<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">101350</article-id><article-id pub-id-type="doi">10.7554/eLife.101350</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Tissue inflammation induced by constitutively active STING is mediated by enhanced TNF signaling</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Luksch</surname><given-names>Hella</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-7070-4992</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Schulze</surname><given-names>Felix</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-8220-5012</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Geißler-Lösch</surname><given-names>David</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0009-0006-8332-2145</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Sprott</surname><given-names>David</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Höfs</surname><given-names>Lennart</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Szegö</surname><given-names>Eva M</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Tonnus</surname><given-names>Wulf</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9728-1413</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Winkler</surname><given-names>Stefan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Günther</surname><given-names>Claudia</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-4330-1861</contrib-id><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Linkermann</surname><given-names>Andreas</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-6287-9725</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Behrendt</surname><given-names>Rayk</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1091-2877</contrib-id><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Teichmann</surname><given-names>Lino L</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9489-7282</contrib-id><xref ref-type="aff" rid="aff7">7</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Falkenburger</surname><given-names>Björn H</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2387-526X</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff8">8</xref><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Rösen-Wolff</surname><given-names>Angela</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9613-5879</contrib-id><email>angela.roesen-wolff@tu-dresden.de</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/042aqky30</institution-id><institution>Department of Pediatrics, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden</institution></institution-wrap><addr-line><named-content content-type="city">Dresden</named-content></addr-line><country>Germany</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/042aqky30</institution-id><institution>Department of Neurology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden</institution></institution-wrap><addr-line><named-content content-type="city">Dresden</named-content></addr-line><country>Germany</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/042aqky30</institution-id><institution>Department of Physiology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden</institution></institution-wrap><addr-line><named-content content-type="city">Dresden</named-content></addr-line><country>Germany</country></aff><aff id="aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/042aqky30</institution-id><institution>Division of Nephrology, Department of Internal Medicine III, Faculty of Medicine and University Hospital Carl Gustav</institution></institution-wrap><addr-line><named-content content-type="city">Dresden</named-content></addr-line><country>Germany</country></aff><aff id="aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/042aqky30</institution-id><institution>Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden</institution></institution-wrap><addr-line><named-content content-type="city">Dresden</named-content></addr-line><country>Germany</country></aff><aff id="aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01xnwqx93</institution-id><institution>Institute for Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn</institution></institution-wrap><addr-line><named-content content-type="city">Bonn</named-content></addr-line><country>Germany</country></aff><aff id="aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01xnwqx93</institution-id><institution>Department of Medicine III, University Hospital Bonn</institution></institution-wrap><addr-line><named-content content-type="city">Bonn</named-content></addr-line><country>Germany</country></aff><aff id="aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/043j0f473</institution-id><institution>Deutsches Zentrum für Neurodegenerative Erkrankungen</institution></institution-wrap><addr-line><named-content content-type="city">Dresden</named-content></addr-line><country>Germany</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Taniguchi</surname><given-names>Tadatsugu</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/057zh3y96</institution-id><institution>University of Tokyo</institution></institution-wrap><country>Japan</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Taniguchi</surname><given-names>Tadatsugu</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/057zh3y96</institution-id><institution>University of Tokyo</institution></institution-wrap><country>Japan</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>20</day><month>03</month><year>2025</year></pub-date><volume>14</volume><elocation-id>e101350</elocation-id><history><date date-type="received" iso-8601-date="2024-07-08"><day>08</day><month>07</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2025-03-17"><day>17</day><month>03</month><year>2025</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2024-04-29"><day>29</day><month>04</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.04.25.591149"/></event></pub-history><permissions><copyright-statement>© 2025, Luksch et al</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Luksch et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-101350-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-101350-figures-v2.pdf"/><abstract><p>Constitutive activation of STING by gain-of-function mutations triggers manifestation of the systemic autoinflammatory disease STING-associated vasculopathy with onset in infancy (SAVI). In order to investigate the role of signaling by tumor necrosis factor (TNF) in SAVI, we used genetic inactivation of TNF receptors 1 and 2 in murine SAVI, which is characterized by T cell lymphopenia, inflammatory lung disease, and neurodegeneration. Genetic inactivation of TNFR1 and TNFR2, however, rescued the loss of thymocytes, reduced interstitial lung disease, and neurodegeneration. Furthermore, genetic inactivation of TNFR1 and TNFR2 blunted transcription of cytokines, chemokines, and adhesions proteins, which result from chronic STING activation in SAVI mice. In addition, increased transendothelial migration of neutrophils was ameliorated. Taken together, our results demonstrate a pivotal role of TNFR signaling in the pathogenesis of SAVI in mice and suggest that available TNFR antagonists could ameliorate SAVI in patients.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>STING</kwd><kwd>SAVI</kwd><kwd>TNF</kwd><kwd>systemic autoinflammation</kwd><kwd>vasculopathy</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>369799452-TRR237</award-id><principal-award-recipient><name><surname>Schulze</surname><given-names>Felix</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>EXC2151 - 390873048</award-id><principal-award-recipient><name><surname>Behrendt</surname><given-names>Rayk</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>TNF signaling contributes significantly to pathology of constitutively active STING in murine STING-associated vasculopathy with onset in infancy disease.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Stimulator of interferon response cGAMP interactor 1 (STING) is a key regulator in innate immunity, especially in the defense against viral infections. Uncontrolled activity of STING results in manifestation of autoinflammatory diseases, e.g., STING-associated vasculopathy with onset in infancy (SAVI) (<xref ref-type="bibr" rid="bib28">Liu et al., 2014</xref>), Parkinson’s disease (<xref ref-type="bibr" rid="bib23">Hinkle et al., 2022</xref>), or severe COVID-19 disease (<xref ref-type="bibr" rid="bib15">Domizio et al., 2022</xref>). Murine SAVI is a well-established model for pathology and signaling of constitutive uncontrolled STING activation (<xref ref-type="bibr" rid="bib57">Warner et al., 2017</xref>). STING is an innate immune receptor that senses cyclic dinucleotides. These can be derived from bacteria or in mammalian cells be produced by the enzyme cyclic GMP-AMP synthase (cGAS), which is activated upon binding to double-stranded DNA. Mammalian cGAS produces the unique 2′3′-cGAMP that binds to STING and results in its translocation, phosphorylation, and oligomerization. STING oligomers recruit TANK-binding kinase 1 (TBK1), which subsequently activates type I interferon (IFN I) signaling as well as nuclear factor κ light chain enhancer of activated B cells (NF-κB) triggered signaling (<xref ref-type="bibr" rid="bib3">Balka et al., 2020</xref>; <xref ref-type="bibr" rid="bib14">de Oliveira Mann et al., 2019</xref>; <xref ref-type="bibr" rid="bib24">Hopfner and Hornung, 2020</xref>). STING signaling is terminated by AP-1-mediated sorting of phosphorylated STING into clathrin-coated transport vesicles that fuse with endolysosomes to degrade STING (<xref ref-type="bibr" rid="bib20">Gonugunta et al., 2017</xref>; <xref ref-type="bibr" rid="bib29">Liu et al., 2022a</xref>).</p><p>Uncontrolled activity of STING is associated with various autoinflammatory disorders and severe diseases caused by viral infections (<xref ref-type="bibr" rid="bib13">Deng et al., 2020</xref>; <xref ref-type="bibr" rid="bib63">Yang et al., 2022</xref>). Gain-of-function mutations of human <italic>STING1</italic> cause SAVI, which is characterized by severe interstitial lung disease, T cell lymphopenia, skin inflammation, and perturbed IFN- and NF-κB-driven signaling (<xref ref-type="bibr" rid="bib11">Clarke et al., 2020</xref>; <xref ref-type="bibr" rid="bib28">Liu et al., 2014</xref>; <xref ref-type="bibr" rid="bib43">Picard et al., 2016</xref>; <xref ref-type="bibr" rid="bib55">Tang et al., 2020</xref>). Genetically induced chronic activation of STING results in comparable severe systemic autoinflammatory symptoms in the murine organism (<xref ref-type="bibr" rid="bib5">Bennion et al., 2019</xref>; <xref ref-type="bibr" rid="bib6">Bennion et al., 2020</xref>; <xref ref-type="bibr" rid="bib18">Gao et al., 2022</xref>; <xref ref-type="bibr" rid="bib32">Luksch et al., 2019</xref>; <xref ref-type="bibr" rid="bib33">MacLauchlan et al., 2023</xref>; <xref ref-type="bibr" rid="bib34">Martin et al., 2019</xref>; <xref ref-type="bibr" rid="bib37">Motwani et al., 2019</xref>; <xref ref-type="bibr" rid="bib44">Platt et al., 2021</xref>; <xref ref-type="bibr" rid="bib49">Shmuel-Galia et al., 2021</xref>; <xref ref-type="bibr" rid="bib50">Siedel et al., 2020</xref>; <xref ref-type="bibr" rid="bib53">Stinson et al., 2022</xref>; <xref ref-type="bibr" rid="bib54">Szego et al., 2022</xref>; <xref ref-type="bibr" rid="bib57">Warner et al., 2017</xref>). We previously established a SAVI mouse model, by knocking in the disease causing variant N153S into the endogenous murine <italic>Sting1</italic> gene (STING ki) resulting in T cell lymphopenia, interstitial lung disease, and systemic autoinflammation (<xref ref-type="bibr" rid="bib32">Luksch et al., 2019</xref>). In addition, STING ki mice show degeneration of dopaminergic neurons induced by neuroinflammation (<xref ref-type="bibr" rid="bib54">Szego et al., 2022</xref>).</p><p>Initially, STING activates various signal transduction pathways and has been assumed to function primarily through type I IFN signaling (<xref ref-type="bibr" rid="bib28">Liu et al., 2014</xref>). Yet, the manifestation of SAVI hallmarks in STING ki mice were unaffected by knockout of cGAS, IFNAR1, IRF3, and IRF7 (<xref ref-type="bibr" rid="bib32">Luksch et al., 2019</xref>; <xref ref-type="bibr" rid="bib50">Siedel et al., 2020</xref>), suggesting that other pathways in the STING signaling cascade are required for SAVI symptoms. In our previous investigations, we observed an elevated transcription of <italic>Tnf</italic> in spleen and thymus of STING ki mice (<xref ref-type="bibr" rid="bib50">Siedel et al., 2020</xref>). In order to test the hypothesis that tumor necrosis factor (TNF) signaling is involved in manifestation and progression of murine SAVI disease, we here used genetic inhibition of TNF receptors.</p><p>TNF, a systemic multifunctional cytokine, is involved in inflammation and immune regulation as well as development of lymphoid organs, and TNF can be produced and secreted by nearly every cell. We established new mouse lines with STING ki in addition to genetic depletion of tumor necrosis factor receptor 1 (TNFR1), tumor necrosis factor receptor 2 (TNFR2), or TNFR1/2. Both receptors are involved in TNF signaling pathways with different functions. TNFR1 is constitutively expressed on almost all cell populations, whereas TNFR2 expression is inducible in specific cell types, e.g., immune and endothelial cells (<xref ref-type="bibr" rid="bib56">Wajant and Siegmund, 2019</xref>). Both receptors are able to bind TNF but only TNFR1 contains an intracellular death domain and is involved in programmed cell death. TNFR2 is associated with survival and proliferation of cells (<xref ref-type="bibr" rid="bib2">Atretkhany et al., 2020</xref>). After binding of ligands, TNF receptors trigger NF-κB-driven signaling, predominantly through TNFR1 whereas TNFR2 activates NF-κB transcription poorly (<xref ref-type="bibr" rid="bib35">McFarlane et al., 2002</xref>). Current publications suggest distinct effects of TNFR1 and TNFR2 in association with different types of inflammation. TNFR1 signaling stimulates proinflammatory responses within the innate immune system. In contrast, actions of TNFR2 are involved in cellular homeostasis and anti-inflammatory responses (<xref ref-type="bibr" rid="bib27">Liang et al., 2022</xref>). Moreover, in the murine model of autoinflammatory familial Mediterranean fever (FMF), both TNF receptors have opposite effects. TNFR1 showed a pathogenic role and TNFR2 a protective role in association with murine FMF (<xref ref-type="bibr" rid="bib48">Sharma et al., 2019</xref>).</p><p>In this work, we observed that pathology in the thymus of SAVI mice was dependent on TNFR1 and TNFR2 signaling whereas signaling through TNFR1 but not on TNFR2-mediated pathology in lungs of STING ki mice. Similarly, the manifestation of dopaminergic neuron degeneration in substantia nigra was dependent on TNFR1/2 signaling. Finally, we investigated the role of constitutive STING activation on the endothelial barrier, which was found to be TNF signaling-dependent. Endothelial cells of STING ki mice induced transmigration of neutrophils in a TNFR1-dependent manner. Overall, our study highlights a pivotal role of TNF signaling in SAVI disease and implies TNF blockade as valuable therapeutic option to ameliorate symptoms of SAVI disease in patients.</p></sec><sec id="s2" sec-type="materials|methods"><title>Materials and methods</title><sec id="s2-1"><title>Animals</title><p>Heterozygous STING N153S/WT mice (STING ki) were previously described (<xref ref-type="bibr" rid="bib32">Luksch et al., 2019</xref>). STING WT and STING ki mice were crossed to <italic>Tnfr1/2</italic><sup>-</sup><italic><sup>/-</sup></italic> mice, kindly provided by Hans-Joachim Anders, Munich, Germany (<xref ref-type="bibr" rid="bib38">Mulay et al., 2017</xref>). All mice were housed at the Experimental Center of the University of Technology Dresden under specific pathogen-free conditions. All mice experiments were approved by the Landesdirektion Sachsen (TVV 4/2019, TVV 13/2019) and carried out in accordance with the institutional guidelines on animal welfare.</p></sec><sec id="s2-2"><title>Cell preparations and flow cytometry</title><p>Spleens and thymi were mechanically homogenized and passed through a 100 µm cell strainer. Single-cell suspensions of spleen, thymi, and blood were obtained by lysis of red blood cells and additional filtration through 30 µm meshes. All cell suspensions were washed with FACS buffer (PBS, 2%FCS, 2.5 mM EDTA). These isolated cells were incubated with fluorescence-labeled antibodies in FACS buffer for 30 min at 4°C. For a detailed overview of used antibodies, see <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1, table S1</xref>. After incubation, cells were washed twice with FACS buffer. Exclusion of dead cells was performed by adding Zombie UV dye (BioLegend, USA). Cells were analyzed by LSR II (BD Biosciences, Germany) and evaluated with FlowJo V10 software (Tree Star, USA).</p></sec><sec id="s2-3"><title>Histology of lung</title><p>Lung tissue was dissected from mice and fixed in 4% formaldehyde for 24 hr at 4°C and embedded in paraffin. Lung tissue sections (thickness of 3 µm) were stained with Mayer’s hemalum (Carl Roth, Germany) and counterstained with eosin (Carl Roth, Germany). For quantification of lung disease, whole tissue sections were scanned by Axio Scan Z1 and ZEN software (both from Zeiss, Germany). ZEN 3.0 (Zeiss, Germany) software was used for evaluation of inflammatory areas in all analyzed lung sections. The area of diseased lung in each section was calculated by inflamed area divided by total area of lung section, excluding large airway spaces.</p></sec><sec id="s2-4"><title>Dye labeling of lymph nodes</title><p>Identification of lymph nodes was performed as described previously (<xref ref-type="bibr" rid="bib22">Harrell et al., 2008</xref>). Briefly, mice were anesthetized and 25 µl of 5% Evans Blue dye in PBS was injected subcutaneously into both hind paws. After 30 min of dye injection, mice were euthanized and dissected for visualization of blue-labeled lymph nodes.</p></sec><sec id="s2-5"><title>Gene expression analysis</title><p>Total RNA of lung and thymi was extracted from snap-frozen tissue by using the RNeasy Mini Kit (QIAGEN, Germany) according to the manufacturer’s instructions and cDNA was generated by MMLV reverse transcription (Promega, Germany). Quantitative real-time PCR assays were carried out by using GoTaq qPCR master mix (Promega, Germany) and QuantStudio 5 (Thermo Fisher Scientific, USA). PCR primers were generated from the Primer Bank database, see <xref ref-type="supplementary-material" rid="supp3">Supplementary file 3, table S3</xref> (<xref ref-type="bibr" rid="bib51">Spandidos et al., 2010</xref>). Expression of genes was normalized with respect to each housekeeping gene using ΔΔCt method for comparing relative expression.</p></sec><sec id="s2-6"><title>LEGENDplex assay</title><p>Mouse cytokine release syndrome panel LEGENDplex (BioLegend, USA) is a multiplex bead-based assay using the basic methodology of ELISA. Snap-frozen lung tissue was extracted by 1% NP-40 (Sigma-Aldrich, Germany) and cOmplete Protease Inhibitor Cocktail (Roche, Germany) in PBS. Collected serum and lung extracts from mice were incubated with bead-conjugated antibodies overnight at 4°C and permanent shaking. Content of chemokines/cytokines was quantified after washing and staining with biotinylated detection antibodies and phycoerythrin-bound streptavidin by using LSR II (BD Biosciences, Germany). Calculation of each chemokine/cytokine quantity was determined by using standard curves according to the manufacturer’s instructions.</p></sec><sec id="s2-7"><title>Immunofluorescence staining of brain sections</title><p>Mice were euthanized with an overdose of isoflurane (Baxter, Belgium) and perfused transcardially with 4% paraformaldehyde (PFA) in Tris-buffered saline (TBS, pH 7.6). The tissue was left in 4% PFA for another 48 hr at 4°C. For cryoprotection, brains were incubated in 30% sucrose in TBS. They were snap-frozen at –55°C in isopentane and stored at –80°C. 30-µm-thick coronal brain sections were obtained using a Cryostat (Leica CM3050 S Biosystems, Germany).</p><p>Brain sections were rinsed in TBS three times for 10 min each. Afterward they were incubated for 1 hr at room temperature in a blocking buffer, which consisted of 10% donkey serum (BIOZOL Diagnostica Vertrieb GmbH, Germany), 0.2% Triton X-100 (Thermo Scientific, USA), and TBS. Incubation with primary antibody was performed by using sheep anti-TH, chicken anti-GFAP, and guinea pig anti-Iba1 (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2, table S2</xref>) at 4°C overnight. After three 10 min rinses with TBS, slices were incubated with fluorophore-conjugated secondary antibodies for 1 hr at room temperature Alexa Fluor 488-conjugated donkey anti-sheep, Alexa Fluor 647-conjugated donkey anti-chicken, CF555-conjugated donkey anti-guinea pig (<xref ref-type="supplementary-material" rid="supp2">Supplementary file 2, table S2</xref>). Hoechst was applied for nuclear counterstaining. Sections were mounted in Fluoromount-G (Invitrogen, USA).</p></sec><sec id="s2-8"><title>Quantification of dopaminergic neurons, astrocytes, and microglia in the SNc</title><p>For each animal, we stained and slide-scanned every fourth brain section. Images were acquired using a spinning disk confocal microscope and a ×20/0.8 objective. The system consists of a Zeiss Axio Observer.Z1 Inverted Microscope (Zeiss, Germany) supported by a Yokogawa CSU-X1 unit (Yokogawa Life Science, Tokyo). Each section was scanned at seven Z-levels with 1 µm intervals and projected according to the ‘Orthogonal projection’ and ‘Stitching’ function in Zeiss Zen 3.1 software (Zeiss, Germany). TH-positive neurons of both hemispheres in the <italic>pars compacta</italic> of the <italic>substantia nigra</italic> (SNc) were manually counted in Zeiss Zen. Based on the TH staining, the SNc was manually encircled. The numbers of Iba1-positive microglia and GFAP-positive astrocytes were also quantified manually in both hemispheres within the marked area. Next, each cell type’s count was summed and multiplied by four since every fourth section was analyzed in order to represent the total number within the SNc. Counts of positive stained cells from STING WT and STING ki mice were normalized to the corresponding mean count in STING WT.</p></sec><sec id="s2-9"><title>Transcriptomic analysis of murine lung endothelial cells</title><p>Murine lung endothelial cells were isolated from perfused (10 U/ml heparin diluted in PBS) lung tissue. Single-cell suspension was obtained after digestion with 1 mg/ml Collagenase (Sigma-Aldrich, Germany), 3.5 mg/ml Dispase (Roche, Germany), and 25 µg/ml DNaseI (Roche, Germany) in native IMDM (Thermo Fisher Scientific, USA) over 45 min at 37°C. Collected cells were washed with PBS and passed through a 30 µm cell strainer. Lung endothelial cells were enriched by positive selection of CD31<sup>+</sup> cells with microbeads (Miltenyi Biotec), according to the manufacturer’s protocol. All selected cells were stained with antibodies (all from BioLegend, USA) against CD45.2 (1:300), CD11b (1:500), Ter-119 (1:500), CD326 (1:500), CD31 (1:300), and separated by FACS Aria. Dead cells and cellular debris were excluded by PI staining. The designed gating strategy ensured the exclusion of leukocytes (CD45.2<sup>+</sup> and CD11b<sup>+</sup>), erythrocytes (Ter-119<sup>+</sup>), and epithelial cells (CD326<sup>+</sup>). Total RNA was extracted by RNeasy Plus Mini Kit (QIAGEN, Germany) and poly-A enriched before library preparation using NEBNext Ultra II Directional RNA Library Prep Kit (NEB, USA). For each library, 30 mio single end reads were generated on an Illumina NovaSeq 6000. Reads were mapped to mouse genome GRCm39 followed by normalization, exploratory, and differential expression analysis using DESeq2 (<xref ref-type="bibr" rid="bib31">Love et al., 2014</xref>). Data are deposited on GEO database, Accession no. GSE244062.</p></sec><sec id="s2-10"><title>Functional assays of murine lung endothelial cells</title><p>Isolation and culture of murine lung endothelial cells was performed as described previously (<xref ref-type="bibr" rid="bib17">Fehrenbach et al., 2009</xref>). In brief, mice were perfused transcardially with 10 U/ml heparin (Carl Roth, Germany) diluted in PBS. Lung tissue was removed and digested with 1 mg/ml Collagenase (Sigma-Aldrich, Germany), 3.5 mg/ml Dispase (Roche, Germany) and 25 µg/ml DNaseI (Roche) in native IMDM (Thermo Fisher Scientific, USA) over 45 min at 37°C. The resulting cell suspension was filtered through a 30 µm cell strainer. The filtered cell suspension was washed in PBS and resuspended in complete IMDM culture medium. The extracted cells of lung tissue were plated into Attachment Factor Protein- (Life Technologies, USA) coated T75 tissue culture flasks for 2 days. After this time, lung cells were detached by Accutase (BioLegend, USA) and the endothelial cells were separated using Dynabeads coupled to anti-CD31 antibody and anti-ICAM2 antibody (BioLegend, USA) according to the manufacturer’s instructions (Thermo Fisher Scientific, USA). Collected murine lung endothelial cells were cultured in coated T75 flasks. Cultured cells from passages 1–3 were used for analyzing neutrophil attachment and neutrophil transendothelial migration.</p><p>For this purpose, 0.3×10<sup>5</sup> lung endothelial cells were seeded into 6-channel µ-Slides VI 0.4 (IBIDI, Germany), which were precoated with attachment factor (Thermo Fisher Scientific, USA). Cells were incubated for 4 days with changing media twice per day. For stimulated cells, last medium exchange was performed with either 5 ng/ml TNF (Peprotech, USA) or 100 ng/ml cLPS (Invivogen, USA) and incubation lasted overnight. For the migration assay, neutrophils were isolated from murine bone marrow using femur and tibia. Neutrophils were separated by gradient centrifugation using Histopaque 1119 and 1077 (Sigma-Aldrich, Germany) according to the manufacturer’s instructions. Neutrophils were washed, counted, and diluted to 1×10<sup>6</sup> cells/ml. Afterward flow was applied to µ slides at a flow rate of 0.5 ml/min (≡0.6 dyn/cm<sup>2</sup>) using a syringe pump for 10 min. Subsequently, 0.6×10<sup>6</sup> neutrophils were injected upstream of the endothelial monolayer via a port. Phase-contrast images (five per each channel) were taken with an AXIO OBSERVER Z1 (Zeiss, Germany) over 20 min at a speed of one image every 10 s. Evaluation of attached and transmigrated cells was performed using ZEN Blue software (Zeiss, Germany).</p></sec><sec id="s2-11"><title>Statistics</title><p>All statistical analyses were performed by using GaphPad Prism 9. In the graphs, markers represent data from individual animals and lines represent means of all mice from the indicated genotype. Grubbs’ test was used to identify outliers. Comparison of two groups was performed by using Mann-Whitney test. For the comparison of more groups, one-way ANOVA including Dunnett’s multiple comparisons test or Kruskal-Wallis test including Dunn’s multiple comparisons test was used. Significance levels in each figure are indicated by symbols with *p≤0.05, **p&lt;0.005, ***p&lt;0.001, ****p&lt;0.0001. Analysis of effect size and power were performed by G*Power 3.1.9.4 and collected in <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4, table S4</xref>, effect size d convention (&lt;0.5 = small, 0.5–0.8=medium, &gt;0.8 = large effect) and effect size f convention (&lt;0.25 = small, 0.25–0.4=medium, &gt;0.4 = large effect).</p></sec></sec><sec id="s3" sec-type="results"><title>Results</title><sec id="s3-1"><title>Knockout of TNFR1 and TNFR2 does not significantly affect the numbers of blood T cell in STING ki mice</title><p>We established the STING ki<italic>;Tnfr1/2 <sup>-/-</sup></italic> mouse line with the combination of the gain-of-function mutation of STING and nonfunctional TNFR1 and TNFR2 as double knockout (TNFR1/2). In addition, we generated two new mouse lines, STING ki;<italic>Tnfr1<sup>-/-</sup></italic> (lacking TNFR1) and STING ki;<italic>Tnfr2<sup>-/-</sup></italic> (lacking TNFR2). At the age of 10 weeks, mice were sacrificed and analyzed extensively in comparison to STING WT and STING ki mice (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref> for STING WT and <xref ref-type="fig" rid="fig1">Figure 1</xref> for STING ki). The genetic deletion of TNFR1, TNFR2 alone or together did not increase body weight in STING ki mice significantly (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). Lack of TNFR1 resulted in elevation of blood CD4<sup>+</sup> T cell and CD8<sup>+</sup> T cell numbers in STING ki;<italic>Tnfr1<sup>-/-</sup></italic> and STING ki;<italic>Tnfr1/2 <sup>-/-</sup></italic> mice (<xref ref-type="fig" rid="fig1">Figure 1B–D</xref>, large effect size f, <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4, table S4</xref>). The frequency of blood CD4<sup>+</sup> naïve T cells (CD62L<sup>hi</sup>, CD44<sup>low</sup>) was increased in STING ki;<italic>Tnfr1<sup>-/-</sup></italic> and STING ki;<italic>Tnfr1/2<sup>-/-</sup></italic> mice in comparison to STING ki mice (<xref ref-type="fig" rid="fig1">Figure 1E</xref>, large effect size f, <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4, table S4</xref>). The absence of TNFR1 or TNFR2 had no protective effect on naïve CD8<sup>+</sup> T cells (<xref ref-type="fig" rid="fig1">Figure 1F</xref>) and all effector T cell (CD62L<sup>low</sup>, CD44<sup>hi</sup>) populations in the blood of all STING ki mice (<xref ref-type="fig" rid="fig1">Figure 1G and H</xref>). In addition, blood myeloid cell numbers were reduced between STING ki with or without TNFR knockout (<xref ref-type="fig" rid="fig1">Figure 1I and J</xref>, large effect size f, <xref ref-type="supplementary-material" rid="supp4">Supplementary file 4, table S4</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Disruption of TNFR signaling did not significantly prevent T cell lymphopenia in blood of STING ki mice.</title><p>(<bold>A</bold>) Normalized body weight of 10-week-old STING ki mice, compared to body weight data from strain C57BL/6NJ (#005304, Jackson Laboratory). (<bold>B</bold>) Representative FACS plots of blood CD4<sup>+</sup> T cells and CD8<sup>+</sup> T cells from STING ki mice on C57BL/6 (BL6) or <italic>Tnfr1/2<sup>-/-</sup></italic> background. (<bold>C</bold>) Numbers of blood CD4<sup>+</sup> T cells in STING ki mice of indicated genotype. (<bold>D</bold>) Numbers of blood CD8<sup>+</sup> T cells in STING ki mice of indicated genotype. (<bold>E</bold>) Frequency of blood naïve (Tn) CD4<sup>+</sup> T cell population in STING ki mice of indicated genotype. (<bold>F</bold>) Frequency of blood naïve (Tn) T cells of CD8<sup>+</sup> T cell population in STING ki mice of indicated genotype. (<bold>G</bold>) Frequency of blood effector (Teff) CD4<sup>+</sup> T cell population in STING ki mice of indicated genotypes. (<bold>H</bold>) Frequency of blood effector (Teff) CD8<sup>+</sup> T cell population in STING ki mice of indicated genotypes. (<bold>I</bold>) Numbers of blood monocytes in STING ki mice of indicated genotypes. (<bold>J</bold>) Numbers of blood neutrophils in STING ki mice of indicated genotypes. Markers represent individual mice, bars represent mean of n=7–8 mice per group pooled from nine independent preparations analyzed by Kruskal-Wallis test including Dunn’s multiple comparisons test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101350-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Disruption of TNFR signaling did not change the T cell numbers in the blood of STING WT mice.</title><p>(<bold>A</bold>) Normalized body weight of 10-week-old STING WT mice, compared to body weight data from strain C57BL/6NJ (#005304, Jackson Laboratory). (<bold>B</bold>) Representative FACS plots of blood CD4<sup>+</sup> T cells and CD8<sup>+</sup> T cells from STING WT mice on C57BL/6 (BL6) or <italic>Tnfr1/2<sup>-/-</sup></italic> background. (<bold>C</bold>) Numbers of blood CD4<sup>+</sup> T cells in STING WT mice of indicated genotype. (<bold>D</bold>) Numbers of blood CD8<sup>+</sup> T cells in STING WT mice of indicated genotype. (<bold>E</bold>) Frequency of blood naïve (Tn) CD4<sup>+</sup> T cell population in STING WT mice of indicated genotype. (<bold>F</bold>) Frequency of blood naïve (Tn) T cells of CD8<sup>+</sup> T cell population in STING WT mice of indicated genotype. (<bold>G</bold>) Frequency of blood effector (Teff) CD4<sup>+</sup> T cell population in STING WT mice of indicated genotypes. (<bold>H</bold>) Frequency of blood effector (Teff) CD8<sup>+</sup> T cell population in STING WT mice of indicated genotypes. The absence of TNFR1/2 led to significant increase of effector CD8<sup>+</sup> T cell number in STING WT mice. (<bold>I</bold>) Numbers of blood monocytes in STING WT mice of indicated genotypes. (<bold>J</bold>) Numbers of blood neutrophils in STING WT mice of indicated genotypes. Markers represent individual mice, bars represent mean of n=7–8 mice per group pooled from nine independent preparations analyzed by Kruskal-Wallis test including Dunn’s multiple comparisons test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101350-fig1-figsupp1-v2.tif"/></fig></fig-group><p>Parallel characterization of these parameters in all STING WT mice (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A–J</xref>) showed no differences with exception of significantly more CD8<sup>+</sup> T effector cells in the blood of TNFR1/2 ko mice (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1H</xref>).</p></sec><sec id="s3-2"><title>Lack of TNFRs partially rescues thymus and spleen pathology in STING ki mice</title><p>The thymus undergoes massive pathological modifications in murine SAVI disease. As previously shown, the numbers of thymocytes were significantly reduced in STING ki mice. Likewise, various inflammatory signaling pathways, detected by gene expression analysis of <italic>Sting1</italic>, <italic>Cxcl10,</italic> and <italic>Tnf,</italic> were upregulated. Finally, these inflammatory processes led to significant functional limitations of T cell maturation in the thymus of STING ki mice (<xref ref-type="bibr" rid="bib50">Siedel et al., 2020</xref>).</p><p>In order to study thymus and spleen pathology here, TNFR knockout mice were sacrificed and analyzed in comparison to respective STING WT and STING ki mice (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref> for STING WT and <xref ref-type="fig" rid="fig2">Figure 2</xref> for STING ki) at the age of 10 weeks.</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Inhibition of TNFR signaling regulates frequencies and numbers of thymic and splenic cells in STING ki mice.</title><p>(<bold>A</bold>) Cellular count of all isolated cells per thymus in STING ki mice of indicated genotype. (<bold>B</bold>) Numbers of DN, (<bold>C</bold>) DP, (<bold>D</bold>) SP CD4<sup>+</sup>, and (<bold>E</bold>) SP CD8<sup>+</sup> thymocytes per thymus in STING ki mice of indicated genotype. (<bold>F</bold>) Relative gene expression of <italic>Cxcl10</italic>, (<bold>G</bold>) <italic>Sting1</italic>, (<bold>H</bold>) <italic>Tnf,</italic> and (<bold>I</bold>) <italic>Il1b</italic> in thymus tissue from STING ki mice of indicated genotype. (<bold>J</bold>) Cellular count of all isolated cells per spleen in STING ki mice of indicated genotype. (<bold>K</bold>) Number of splenic CD4<sup>+</sup> T cells, (<bold>L</bold>) splenic CD8<sup>+</sup> T cells, (<bold>M</bold>) splenic monocytes, and (<bold>N</bold>) splenic neutrophils in STING ki mice of indicated genotypes. Markers represent individual mice, bars represent mean of n=7–8 mice per group pooled from nine independent preparations analyzed by Kruskal-Wallis test including Dunn’s multiple comparisons test. *p&lt;0.05, **p&lt;0.005, ***p&lt;0.001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101350-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Inhibition of TNFR signaling did not affect frequencies and numbers of thymic and splenic cells in STING WT mice.</title><p>(<bold>A</bold>) Cellular count of all isolated cells per thymus in STING WT mice of indicated genotype. (<bold>B</bold>) Numbers of DN, the loss of TNFR2 function in STING WT mice resulted in a reduction of DN cell number, (<bold>C</bold>) DP, (<bold>D</bold>) SP CD4<sup>+</sup>, and (<bold>E</bold>) SP CD8<sup>+</sup> thymocytes per thymus in STING WT mice of indicated genotype. (<bold>F</bold>) Relative gene expression of <italic>Cxcl10</italic>, (<bold>G</bold>) <italic>Sting1</italic>, (<bold>H</bold>) <italic>Tnf,</italic> and (<bold>I</bold>) <italic>Il1b</italic> in thymus tissue from STING WT mice of indicated genotype. (<bold>J</bold>) Cellular count of all isolated cells per spleen in STING WT mice of indicated genotypes. (<bold>K</bold>) Number of splenic CD4<sup>+</sup> T cells, (<bold>L</bold>) splenic CD8<sup>+</sup> T cells, (<bold>M</bold>) splenic monocytes, and (<bold>N</bold>) splenic neutrophils in STING WT mice of indicated genotypes. Markers represent individual mice, bars represent mean of n=7–8 mice per group pooled from nine independent preparations analyzed by Kruskal-Wallis test including Dunn’s multiple comparisons test. *p&lt;0.05.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101350-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Inhibition of TNFR signaling could not restore the development of lymph nodes.</title><p>(<bold>A</bold>) Representative images of blue stained popliteal lymph nodes (white arrow) and (<bold>B</bold>) iliac lymph nodes (white arrow) of STING WT and STING ki mice with indicated genotype.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101350-fig2-figsupp2-v2.tif"/></fig></fig-group><p>Knockout of TNFR1, 2 or double knockout of 1 and 2 (1/2) was first studied in comparison to STING WT;BL6 mice. As shown in <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>, knockout of TNFR signaling resulted in unaltered thymic cellular content (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). Double negative cells were slightly reduced by TNFR2 knockout (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>) while DP cells, SP CD4<sup>+</sup> and SP CD8<sup>+</sup> cells were unchanged (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1C–E</xref>). Transcription of <italic>Cxcl10</italic>, <italic>Sting1,</italic> and <italic>TNF</italic> was unaltered (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1F–H</xref>). However, transcription of <italic>Il1b</italic> was elevated in TNFR1 and TNFR2 knockout mice (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1I</xref>), albeit unaltered in TNFR1/2 knockout mice in comparison to STING WT;BL6. The total splenic cell content was not altered in TNFR1 and TNFR2 knockout mice, respectively (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1J</xref>) and the numbers of CD4<sup>+</sup> and CD8<sup>+</sup> T cells were reduced in the spleens of TNFR1/2 knockout mice (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1K and L</xref>). Numbers of mononuclear cells did not vary between these genotypes (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1M and N</xref>). These observations are in accordance with previously published data (<xref ref-type="bibr" rid="bib16">Erickson et al., 1994</xref>; <xref ref-type="bibr" rid="bib40">Peschon et al., 1998</xref>; <xref ref-type="bibr" rid="bib42">Pfeffer et al., 1993</xref>).</p><p>In STING ki mice lacking TNFR1 or TNFR1/2, we found that total thymic cellular count was slightly elevated (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). The absolute numbers in the DN and DP stages were unaffected in STING ki mice by the lack of TNFR1 and/or TNFR2 (<xref ref-type="fig" rid="fig2">Figure 2B and C</xref>). However, deletion of TNFR1/2 signaling induced a significant increase in cellular count of thymic SP CD4<sup>+</sup> and SP CD8<sup>+</sup> in STING ki mice (<xref ref-type="fig" rid="fig2">Figure 2D and E</xref>).</p><p>Interestingly, disruption of TNFR signaling resulted in lower transcription of various signaling pathways. Thymocytes of STING ki mice lacking TNFR1/2 expressed significantly lower levels of IFN-related genes (<italic>Cxcl10</italic>, <italic>Sting1</italic>) (<xref ref-type="fig" rid="fig2">Figure 2F and G</xref>) and mice lacking TNFR1 and TNFR1/2 expressed reduced levels of NF-κB-related genes (<italic>Tnf</italic>, <italic>Il1b</italic>) compared to STING ki mice with functional TNFR (<xref ref-type="fig" rid="fig2">Figure 2H and I</xref>). Obviously, lack of TNFR1 signaling pathways resulted in marked reduction of proinflammatory transcription, potentially causing improvement of physiological function of the thymus in STING ki mice.</p><p>In addition, absence of both TNFRs together resulted in an attenuated severity of splenomegaly (<xref ref-type="fig" rid="fig2">Figure 2J</xref>). The functional loss of TNFR1 or TNFR2 alone had no impact on the manifestation of splenomegaly in STING ki mice. We observed a decrease in splenic CD4<sup>+</sup> T cell numbers in STING ki mice lacking TNFR2 (<xref ref-type="fig" rid="fig2">Figure 2K</xref>). Numbers of splenic CD4<sup>+</sup> and CD8<sup>+</sup> T cells were similar in STING ki;<italic>Tnfr1<sup>-/-</sup></italic> and STING ki;<italic>Tnfr1/2<sup>-/-</sup></italic> mice (<xref ref-type="fig" rid="fig2">Figure 2K and L</xref>). Furthermore, the spleens contained significantly fewer myeloid cells (monocytes and neutrophils) in STING ki;<italic>Tnfr1/2<sup>-/-</sup></italic> mice compared to STING ki;BL6 mice (<xref ref-type="fig" rid="fig2">Figure 2M and N</xref>). Taken together, constitutive activation of STING in STING ki mice severely affected SP CD4<sup>+</sup> and SP CD8<sup>+</sup> T cells in the thymus. The content of CD8<sup>+</sup> T cells in spleens of STING ki mice was independent of TNFR signaling. However, the numbers of CD4<sup>+</sup> T cells in STING ki;<italic>Tnfr2<sup>-/-</sup></italic> mice were dependent on TNFR2 signaling and the presence of myeloid cells in the spleen of STING ki mice depended on combined signaling of TNFR1 and TNFR2.</p></sec><sec id="s3-3"><title>Lack of TNFRs does not restore the formation of lymph nodes in STING ki mice</title><p>Constitutive activation of STING N153S in mice led to blockade of lymph node development (<xref ref-type="bibr" rid="bib6">Bennion et al., 2020</xref>). After dye injection, we detected stained popliteal and iliac lymph nodes only in STING WT mice, not in STING ki mice. Deletion of TNFR1 or/and TNFR2 had no influence on lymph node development in STING ki mice (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2A and B</xref>).</p></sec><sec id="s3-4"><title>Neuroinflammation and neurodegeneration in dependency of TNFR1/2 signaling</title><p>The extent of inflammation in mouse brain resulting from constitutive activation of STING N153S was reported by quantifying the density of Iba1-positive microglia (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Consistent with our previous findings (<xref ref-type="bibr" rid="bib54">Szego et al., 2022</xref>), the density of Iba1-positive microglia in the <italic>substantia nigra</italic> was higher in STING ki;BL6 mice than in STING WT mice (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). TNFR deficiency did not affect neuroinflammation because there was no significant difference between the density of Iba1-positive microglia between STING ki;BL6 mice and STING ki;<italic>Tnfr1/2<sup>-/-</sup></italic> mice (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). This suggests that the TNF pathway is not required for STING-induced microglia activation in the <italic>substantia nigra</italic>.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Lack of TNFR signaling improves the number of dopaminergic neurons in the <italic>substantia nigra</italic> of STING ki mice.</title><p>(<bold>A</bold>) Representative images of TH-positive dopaminergic neurons, Iba1-positive microglia, and GFAP-positive astrocytes in the <italic>substantia nigra pars compacta</italic> (SNc, encircled area) of indicated genotypes. Scale bar represents 200 µm. (<bold>B–D</bold>) Number of Iba1-positive (<bold>B</bold>), GFAP-positive (<bold>C</bold>), TH-positive (<bold>D</bold>) cells in the SNc of the indicated genotypes expressed relative to the number of TH-positive neurons in the SNc of the corresponding mouse line without STING ki. Markers represent individual mice. Bars represent mean of all n=5–6 per group pooled from two independent preparations. Analysis by Mann-Whitney test. *p&lt;0.05.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101350-fig3-v2.tif"/></fig><p>In addition, we measured the extent of STING-induced astrogliosis by quantifying the density of GFAP-positive cells (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Consistent with our previous findings, the density of GFAP-positive astroglia was higher in STING ki than in STING WT mice (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). Yet, as for microglia, there was no significant difference between the density of GFAP-positive astroglia between STING ki;BL6 mice and STING ki;<italic>Tnfr1/2<sup>-/-</sup></italic> mice (<xref ref-type="fig" rid="fig3">Figure 3C</xref>), suggesting that the TNF pathway is not required for STING-induced astrogliosis in the <italic>substantia nigra</italic>.</p><p>Finally, we measured the extent of STING-induced neurodegeneration by quantifying the density of TH-positive dopaminergic neurons in the <italic>substantia nigra</italic> (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). As in our previous findings, the density of TH-positive neurons was lower in STING ki;BL6 mice than in STING WT mice (<xref ref-type="fig" rid="fig3">Figure 3D</xref>). The density of TH-positive neurons in the <italic>substantia nigra</italic> of STING ki;<italic>Tnfr1/2<sup>-/-</sup></italic> mice was higher than the density of TH-positive neurons in the <italic>substantia nigra</italic> of STING ki;BL6 mice (<xref ref-type="fig" rid="fig3">Figure 3D</xref>), suggesting that the STING-induced degeneration of TH-positive neurons was blunted in <italic>Tnfr1/2<sup>-/-</sup></italic> mice and that TNFR1/2 are involved in the STING-induced degeneration of dopaminergic neurons.</p><p>Hence, there is a discrepancy between STING-induced effects on glial cells as opposed to STING-induced effects on neurons. The dependence of STING-induced neurodegeneration but not glial response on TNFR1/2 suggests that the STING-induced degeneration of dopaminergic neurons is not a direct consequence of microglia or astroglia activation. This is consistent with the emerging concept of a neuron-specific inflammatory response (<xref ref-type="bibr" rid="bib58">Welikovitch et al., 2020</xref>).</p></sec><sec id="s3-5"><title>TNFR1 signaling drives SAVI-associated lung inflammation in STING ki mice</title><p>STING N153S gain-of-function mutation induces lethal inflammatory lung disease, a hallmark of SAVI disease. We previously demonstrated that interstitial lung disease developed largely independent of the IFN I signaling, and occurs in the absence of cGAS, IRF3, IRF7, and of IFNAR1 (<xref ref-type="bibr" rid="bib32">Luksch et al., 2019</xref>).</p><p>Inactivation of TNFR2 in STING ki mice only mildly reduced the transcription of SAVI-associated cytokines in lung tissue, while lack of TNFR1 led to a much stronger reduction of interferon-driven <italic>Cxcl10</italic>, <italic>Sting1,</italic> and NF-κB-driven <italic>Tnf</italic> or <italic>Il1b</italic> transcripts. Strikingly, co-deletion of both, <italic>Tnfr1</italic>/<italic>Tnfr2</italic> genes, completely rescued the inflammatory transcriptional signature in lungs of STING ki mice compared to STING WT mice (<xref ref-type="fig" rid="fig4">Figure 4A–D</xref>; <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A–D</xref>). Interestingly, on the protein level, only loss of TNFR1 or TNFR1/2 signaling reduced the amounts of produced CCL2 and IL-6 in lungs of STING ki mice, while loss of TNFR2 signaling alone had no effect (<xref ref-type="fig" rid="fig4">Figure 4E and F</xref>; <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1E and F</xref>). However, this effect appeared to be tissue-specific, as we failed to detect a reduction of systemic proinflammatory cytokines in serum (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1H–O</xref>).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Knockout of TNFR signaling prevents manifestation of severe inflammatory lung disease in STING ki mice.</title><p>(<bold>A</bold>) Gene expression of <italic>Cxcl10</italic>, (<bold>B</bold>) <italic>Sting1</italic>, (<bold>C</bold>) <italic>Tnf,</italic> and (<bold>D</bold>) <italic>Il1b</italic> in lung tissue from STING ki mice of indicated genotype. (<bold>E</bold>) Content of CCL2 and (<bold>F</bold>) IL-6 in lung tissue extracts from STING ki mice of indicated genotype. (<bold>G</bold>) Representative H/E lung sections of 10-week-old STING WT and STING ki mice of indicated genotype. (<bold>H</bold>) Quantification of lung disease severity from STING ki mice of indicated genotypes, data were analyzed by one-way ANOVA including Dunnett’s multiple comparisons test. Markers represent individual mice, bars represent mean of n=7–8 mice per group pooled from nine independent preparations analyzed by Kruskal-Wallis test including Dunn’s multiple comparisons test. *p&lt;0.05, **p&lt;0.005, ****p&lt;0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101350-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Knockout of TNFR signaling did not affect the content of serum chemokines and cytokines.</title><p>(<bold>A</bold>) Gene expression of <italic>Cxcl10</italic>, (<bold>B</bold>) <italic>Sting1</italic>, (<bold>C</bold>) <italic>Tnf,</italic> and (<bold>D</bold>) <italic>Il1b</italic> in lung tissue from STING WT mice of indicated genotype. (<bold>E</bold>) Content of CCL2 and (<bold>F</bold>) IL-6 in lung tissue extracts from STING WT mice of indicated genotype. (<bold>G</bold>) Quantification of lung disease severity from STING WT mice of indicated genotype. (<bold>H</bold>) Content of serum CXCL9 in STING ki mice, (<bold>I</bold>) serum CXCL9 in STING WT mice, (<bold>J</bold>) serum CXCL10 in STING ki mice, (<bold>K</bold>) serum CXCL10 in STING WT mice, (<bold>L</bold>) serum CCL2 in STING ki mice, (<bold>M</bold>) serum CCL2 in STING WT mice, (<bold>N</bold>) serum IL-6 in STING ki mice, and (<bold>O</bold>) serum IL-6 in STING WT mice of indicated genotype. Markers represent individual mice, bars represent mean of n=7–8 mice per group pooled from nine independent preparations analyzed by Kruskal-Wallis test including Dunn’s multiple comparison test.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101350-fig4-figsupp1-v2.tif"/></fig></fig-group><p>In our STING ki mice, carrying the N153S mutation, approximately 14% of the lung area were infiltrated by immune cells (<xref ref-type="fig" rid="fig4">Figure 4G and H</xref>; <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1G</xref>). Development of interstitial lung disease in STING ki mice was almost completely prevented by inactivation of TNFR1 (infiltration&lt;0.5% of lung area) but not of TNFR2. Likewise, STING ki;<italic>Tnfr1/2</italic><sup>-</sup><italic><sup>/-</sup></italic> mice were completely devoid of lung inflammation. Collectively, our data suggest that the secretion of inflammatory cytokines and subsequent inflammation of lungs in STING ki mice are driven by aberrant signaling through TNFR1.</p></sec><sec id="s3-6"><title>Lack of TNFR1/2 abrogates pathologic phenotype in primary lung endothelial cells</title><p>Lung inflammation in STING ki mice manifested around pulmonary blood vessels. We hypothesized that lung endothelial cells could be involved in the development of interstitial lung disease. To address this, we isolated primary murine lung endothelial cells from STING WT, STING ki, and STING WT;<italic>Tnfr1/2<sup>-/-</sup></italic> and STING ki;<italic>Tnfr1/2</italic><sup>-</sup><italic><sup>/-</sup></italic> mice and subjected them to bulk RNAseq. Analysis of the primary lung endothelial transcriptomes revealed a decreased transcription of several proinflammatory cytokines (e.g. <italic>Tnf</italic>, <italic>Il1b</italic>) and chemokines (e.g. <italic>Cxcl1</italic>, <italic>Cxcl2</italic>, <italic>Cxcl9</italic>, <italic>Cxcl10</italic>, <italic>Ccl2</italic>, <italic>Ccl3,</italic> and <italic>Ccl4</italic>) in STING ki mice lacking TNFR1/2 compared to STING ki mice (<xref ref-type="fig" rid="fig5">Figure 5A–C</xref>). Interestingly, chemokines CCL2, CCL3, and CCL4 are essential for the attachment of leukocytes and subsequent migration across the endothelial barrier (<xref ref-type="bibr" rid="bib47">Roblek et al., 2019</xref>; <xref ref-type="bibr" rid="bib52">Stamatovic et al., 2003</xref>). Furthermore, we observed a strongly reduced expression of several cell adhesions molecules (<italic>Jam3</italic>, <italic>Itgam</italic>, <italic>Vcam1</italic>, <italic>Glycam1</italic>, <italic>Madcam1</italic>, <italic>Ncam2,</italic> and <italic>Icam1</italic>) and matrix metalloproteinase 9 (<italic>Mmp9</italic>), all of which are essential for transmigration of leukocytes. This suggests that loss of complete TNFR signaling reverts the inflammatory state of primary lung endothelial cells in STING ki mice, including their transcriptional transmigration signature.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>TNFR signaling is required for the transcriptional upregulation of inflammatory mediators and adhesion factors in murine lung endothelial cells from STING ki mice.</title><p>Heatmap of normalized read counts for indicated transcript, summarized in specific pathways after bioinformatics analysis using DAVID (Database for Annotation, Visualization, and Integrated Discovery, LHRI). (<bold>A</bold>) Cytokine-cytokine receptor interaction. (<bold>B</bold>) Chemokine signaling pathway. (<bold>C</bold>) Cell adhesion molecules and leukocyte transendothelial migration. Remarkable genes are highlighted in bold and red letters. (<bold>D–G</bold>) Analysis of neutrophil attachment and transmigration across endothelial cell monolayers under flow. Schematic representations (left) of experimental setup, circles demonstrate neutrophils; ovals demonstrate endothelial cells, black shapes for STING WT, and red shapes for STING ki genotype. All experimental setups were performed with endothelial cell monolayer without preincubation (medium) or preincubation with TNF or LPS. Quantification of attached neutrophils (medium, TNF, LPS) and transendothelial migrated (TEM) neutrophils (after LPS preincubation = LPS-TEM). (<bold>D</bold>) Influence of STING ki endothelial cells compared to STING WT endothelial cells in attachment and transmigration of STING WT neutrophils. (<bold>E</bold>) Attachment and transmigration of STING ki neutrophils across the endothelial cell monolayer of indicated genotypes (STING WT or STING ki). (<bold>F</bold>) Influence of STING WT or STING ki neutrophils on their attachment and transmigration on STING WT endothelial cell monolayer. (<bold>G</bold>) Attachment and transmigration of STING WT or STING ki neutrophils across the STING ki endothelial cell monolayer. Markers represent separate measurements, bars represent mean of n=6–12 murine lung endothelial monolayers with five analyzed fields of view per sample analyzed by Mann-Whitney test. *p&lt;0.05, **p&lt;0.005, ***p&lt;0.001, ****p&lt;0.0001.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101350-fig5-v2.tif"/></fig><p>Currently it is unclear if immune activation of lung endothelium is functionally involved in the development of SAVI lung disease. To address this, we established a cell culture system for quantification of neutrophil adhesion and neutrophil transmigration across a confluent endothelial cell monolayer under flow. Freshly isolated neutrophils from bone marrow of mice were added to cultured primary lung endothelial cell monolayers. All cells were exposed under constant flow pressure, which mimics physiological shear flow conditions. Quantification of attached and transmigrated neutrophils was performed by real-time microscopic supported video documentation. In the first setup, we used cultured endothelial cells from STING WT and STING ki mice, respectively (<xref ref-type="fig" rid="fig5">Figure 5D and E</xref>). Isolated neutrophil cells of STING WT mice attached significantly more frequently to STING ki endothelial cells than to STING WT endothelial cells (<xref ref-type="fig" rid="fig5">Figure 5D</xref>), even without preincubation of the endothelial cell monolayer. We previously demonstrated that chronic activation of STING in STING N153S mice induced elevated transcription and production of TNF in the lung tissue. To mimic this, we preincubated the endothelial cell monolayer with TNF overnight. The attachment of STING WT neutrophils was much stronger after preincubation of endothelial cells with TNF compared to untreated cells. The reinforcement of proinflammatory signaling after preincubation with TNF resulted in elevated counts of attached (STING WT) neutrophils on STING ki endothelial cell monolayer compared to STING WT endothelial cell monolayers.</p><p>Many SAVI patients suffer from recurrent bacterial infections in the lungs (<xref ref-type="bibr" rid="bib28">Liu et al., 2014</xref>). For analysis of endothelial cell function during bacterial infection, we preincubated the endothelial cell monolayer with LPS overnight. Similar to TNF pretreatment, the attachment of STING WT neutrophils was increased on LPS-exposed STING ki endothelial cells compared to STING WT. LPS also increased transendothelial migration (TEM) of STING WT neutrophils across the STING ki endothelial cell monolayer compared to STING WT endothelial cells (<xref ref-type="fig" rid="fig5">Figure 5D</xref>).</p><p>Next, we used neutrophils from STING ki mice for the investigation of STING WT and STING ki endothelial cell function (<xref ref-type="fig" rid="fig5">Figure 5E</xref>). More STING ki neutrophils attached to STING ki than to STING WT endothelial cell monolayer, independent of their preincubation. Similarly, we observed that significantly more neutrophils transmigrated across STING ki endothelial cell monolayer compared to STING WT endothelial cell monolayers. We conclude that attachment and transmigration of neutrophil cells were dependent on expression of STING gain-of-function mutation in endothelial cells. Taken together, STING ki endothelial cells supported the process of attachment and transmigration significantly more than STING WT endothelial cells.</p><p>In the next setup, we investigated the influence of the neutrophil genotype on the process of cell adhesion and transmigration (<xref ref-type="fig" rid="fig5">Figure 5F and G</xref>). Only after TNF or LPS preincubation of endothelial cell monolayer (STING WT), we observed an effective cell attachment. However, we could not detect any differences in transmigration of neutrophil cells of both genotypes (<xref ref-type="fig" rid="fig5">Figure 5F</xref>). This is in line with the observation of STING WT or STING ki neutrophil cell attachment on STING ki endothelial cell monolayer (<xref ref-type="fig" rid="fig5">Figure 5G</xref>). We did not detect any differences in cell attachment without pretreatment and in transmigration of STING WT and STING ki neutrophils. Taken together, STING ki endothelial cells promote neutrophil attachment and transmigration independent of neutrophil genotype (STING WT or STING ki). Attachment and transmigration of leukocytes are elementary mechanisms in the manifestation and progression of SAVI-driven inflammatory lung disease in STING ki mice.</p><p>Collectively, we demonstrate that lung inflammation of murine SAVI disease in STING N153S mice activated lung endothelial cells leading to increased attachment and transmigration of immune cells. Furthermore, our data suggests a pivotal role of TNFR1 signaling in the development of interstitial lung disease, which might have major implications for the treatment of human SAVI and other pulmonary inflammatory conditions with similar clinical symptoms.</p></sec></sec><sec id="s4" sec-type="discussion"><title>Discussion</title><p>In this work, we performed the inhibition of TNF signaling by generation of TNFR signaling-deficient mouse model with simultaneous chronic activation of STING caused by STING ki reduced some – but not all – consequences of constitutively active STING.</p><p>Constitutive activation of STING results in uncontrolled elevation of NF-κB signaling pathways, demonstrated by upregulated <italic>Tnf</italic> expression in STING ki mice (<xref ref-type="bibr" rid="bib54">Szego et al., 2022</xref>).</p><p>For in-depth analysis of STING-dependent TNF expression, we used TNFR signaling-deficient STING ki mice. We observed improvement of thymocyte counts in STING ki mice lacking TNFR1 and TNFR1/2. Blockade of TNFR signaling, especially signaling of TNFR1, increased survival of thymocytes (SP CD8 cells) and enabled the enlargement of the peripheral T cell pool. Interestingly, the frequency of naïve T cells and effector T cells was unchanged in all analyzed STING ki mice. This indicates that blockade of TNFR signaling can promote the cellularity of thymocytes, but does not influence the activation of peripheral T cells. These results are in agreement with previously published data showing that systemic inflammation driven by TNFR signaling induced severe thymic atrophy. This phenotype was rescued totally in a TNFR1-deficient background (<xref ref-type="bibr" rid="bib4">Belhacéne et al., 2012</xref>). We previously reported that STING ki mice show a disturbed development of lymph nodes leading to the complete loss of lymph nodes (<xref ref-type="bibr" rid="bib6">Bennion et al., 2020</xref>). We found that the absence of TNFR1 signaling did normalize the thymocyte numbers, but did not restore the development of lymph nodes in STING ki mice. In contrast, STING ki mice lacking the IFNGR1 showed a successful lymph node development, but no improvement of thymocyte development (<xref ref-type="bibr" rid="bib53">Stinson et al., 2022</xref>). These observations suggest that T cell development in the thymus is dependent on TNFR1 signaling, but the development of lymph nodes depends on IFNGR1 signaling.</p><p>Manifestation and progression of severe interstitial lung disease is a dominant hallmark of the murine systemic autoinflammatory SAVI disease (<xref ref-type="bibr" rid="bib57">Warner et al., 2017</xref>). It was not possible to improve the severity of lung disease by a curative bone marrow transplantation in STING ki mice (<xref ref-type="bibr" rid="bib32">Luksch et al., 2019</xref>). We observed a strong increase of type I IFN and type II IFN signaling as well as elevated transcription of proinflammatory mediators, e.g., <italic>Tnf</italic> and <italic>Il1b</italic> in lung tissue of STING ki mice. The manifestation of this inflammatory lung disease was independent of type I IFN, but depended on type II IFN signaling (<xref ref-type="bibr" rid="bib53">Stinson et al., 2022</xref>). Our results demonstrated impressive that the initiation and progression of severe lung disease in STING ki mice is also dependent on TNFR1 signaling. In contrast, the deletion of TNFR2 in STING ki mice did not improve the severity of inflammatory lung disease. This is in line with a report that TNFR1 deficiency inhibited skin inflammation and TNFR2 deficiency rather promoted the development of skin disease in a mouse psoriasis model (<xref ref-type="bibr" rid="bib9">Chen et al., 2021</xref>).</p><p>The STING-induced degeneration of dopaminergic neurons in the substantia nigra was reduced in mice with TNFR1/2 deficiency (<xref ref-type="fig" rid="fig3">Figure 3D</xref>), whereas the activation of astroglia and microglia was not (<xref ref-type="fig" rid="fig3">Figure 3B and C</xref>). Neurons express both TNFRs, so circulating TNF could affect dopaminergic neurons without involvement of glial cells. Indeed, elevated levels of TNF have been implicated in the degeneration of dopaminergic neurons (<xref ref-type="bibr" rid="bib21">Harms et al., 2021</xref>; <xref ref-type="bibr" rid="bib59">Williams-Gray et al., 2016</xref>). For instance, anti-TNF therapy reduced the incidence of PD in patients with inflammatory bowel disease (<xref ref-type="bibr" rid="bib41">Peter et al., 2018</xref>), and polymorphisms in the TNF gene have been associated with an increased risk for PD (<xref ref-type="bibr" rid="bib10">Chu et al., 2012</xref>; <xref ref-type="bibr" rid="bib39">Nishimura et al., 2001</xref>).</p><p>The preserved activation of glial cells in STING ki;<italic>Tnfr1/2<sup>-/-</sup></italic> mice indicates that their activation does not require TNFRs. Genetic inactivation of <italic>Casp1</italic> in STING ki mice blocked IL-1β activation, NRLP3 inflammasome formation, and activation of astroglia but not microglia (<xref ref-type="bibr" rid="bib54">Szego et al., 2022</xref>), suggesting that astroglia activation could be mediated by NLRP3-IL-1β signaling. Activation of microglia was affected only moderately by genetic inactivation of interferon receptor 1 (<italic>Ifnar1<sup>-/-</sup></italic>), suggesting that it is not dependent on this pathway.</p><p>For determination of essential mediators in the manifestation of SAVI characteristic lung disease, we performed a transcriptome analysis of freshly isolated murine lung endothelial cells. We found a significantly decreased expression of various proinflammatory mediators and their receptors in the lung endothelial cells of STING ki;<italic>Tnfr1/2<sup>-/-</sup></italic> mice in comparison to STING ki mice. Remarkably, transcription of type II IFN-driven <italic>Cxcl9</italic>, <italic>Cxcl10,</italic> and NF-κB-driven <italic>Tnf</italic> and <italic>Il1b</italic> was downregulated in all analyzed STING ki mice with deletion of TNFR1 and TNFR2 compared to STING ki mice. This is in line with previously described results that lack of IFNGR1 in STING ki mice prevent uncontrolled upregulation of <italic>Cxcl9</italic> and <italic>Cxcl10</italic> gene expression (<xref ref-type="bibr" rid="bib53">Stinson et al., 2022</xref>). The complete evaluation of RNA sequencing data of primary lung endothelial cells disclosed the involvement of chemokines and adhesions proteins in the manifestation of SAVI characteristic inflammatory lung disease. Transcription of <italic>Ccl2</italic>, <italic>Ccl3,</italic> and <italic>Ccl4</italic> was downregulated in endothelial cell of STING ki mice lacking TNFR1/2 signaling. The chemokine CCL2 induces cytoskeletal alterations in endothelial cells and is essential for recruitment and migration of neutrophil granulocytes across the endothelial barrier in mouse tumor models (<xref ref-type="bibr" rid="bib47">Roblek et al., 2019</xref>). Additionally, endothelial secretion of CCL2 controls metastasis by promoting tumor cell extravasation (<xref ref-type="bibr" rid="bib60">Wolf et al., 2012</xref>). In mice, CCL3 recruits neutrophil granulocytes to the lung in response to IFNγ-mediated signaling in a virus infection model (<xref ref-type="bibr" rid="bib8">Bonville et al., 2009</xref>). In LPS-induced lung inflammation, CCL2 recruits macrophages and neutrophil granulocytes into lung tissue across the endothelial barrier (<xref ref-type="bibr" rid="bib36">Mercer et al., 2014</xref>). The presence of CCL2 induces brain endothelial hyperpermeability and attracts leukocytes to murine brain endothelial cells (<xref ref-type="bibr" rid="bib52">Stamatovic et al., 2003</xref>). Human gain-of-function mutations of <italic>STING1</italic> induced elevated transcription of <italic>CCL3</italic>, <italic>CCL4,</italic> and <italic>IL6</italic> in PBMCs from SAVI patients (<xref ref-type="bibr" rid="bib12">de Cevins et al., 2023</xref>). Taken together, the increased expression of endothelial <italic>Ccl2</italic>, <italic>Ccl3,</italic> and <italic>Ccl4</italic> is necessary for leukocyte transmigration into the lung tissue in the context of virus- or bacteria-induced inflammation, autoinflammation, and tumor-promoting metastasis. For transmigration of cells across the endothelial barrier, the presence of these chemokines is essential (<xref ref-type="bibr" rid="bib36">Mercer et al., 2014</xref>).</p><p>Constitutively active STING induces activation of different pathways, e.g., interferon- or NF-κB-driven signaling. Our results demonstrate that proinflammatory mediators are much more produced in primary lung endothelial cells of SAVI mice. We assume that this uncontrolled signaling is essential for endothelial barrier dysfunction and finally for accumulation of leukocytes in the lung tissue. Primary lung endothelial cells of STING ki mice allowed more attachment of neutrophils compared to primary lung endothelial cells of STING WT mice. We pointed out that attachment and transmigration under native condition was independent of neutrophil genotype. These results demonstrated clearly that the intact barrier of lung endothelial cells is a critical factor for the manifestation of severe inflammatory lung disease. In a murine peritonitis model, it was demonstrated that the expression of STING in endothelial cells is essential for leukocyte transmigration (<xref ref-type="bibr" rid="bib1">Anastasiou et al., 2021</xref>). Endothelial cells isolated from human coronary artery produce high amounts of adhesions proteins, e.g., ICAM1, that support the transendothelial migration of leukocytes (<xref ref-type="bibr" rid="bib62">Xue et al., 2018</xref>). In human umbilical vein endothelial cells (stimulated with TNF), several alterations in gene transcription were observed, e.g., elevated transcription of proinflammatory mediators and adhesion proteins as well as decreased transcription of cytoskeletal components (<xref ref-type="bibr" rid="bib46">Rhead et al., 2020</xref>; <xref ref-type="bibr" rid="bib64">Zhou et al., 2002</xref>). This altered signaling led to molecular alterations in endothelial cells and disrupted the endothelial cell barrier. Interestingly, the mouse model for acute lung injury induced by LPS inhalation is characterized by elevated STING expression (<xref ref-type="bibr" rid="bib61">Wu et al., 2022</xref>). Pharmacological inhibition of STING activation prevented the manifestation of this disease. In the same line it was published that the progression of ANCA-associated vasculitis is dependent on the activation of cGAS/STING/IRF3 axis (<xref ref-type="bibr" rid="bib26">Kessler et al., 2022</xref>). Blockade of STING activation improved the severity of this disease significantly. Previous murine studies indicated that the expression of STING V154M in endothelial cells is only essential for manifestation of inflammatory infiltrates (<xref ref-type="bibr" rid="bib19">Gao et al., 2024</xref>). Taken together, the chronic activity of STING in endothelial cells of STING ki mice is important for disruption of endothelial cell barrier and manifestation of severe lung disease.</p><p>Stinson and coauthors described that murine SAVI disease is promoted by IFNγ signaling (<xref ref-type="bibr" rid="bib53">Stinson et al., 2022</xref>) and we here observed a TNFR1 signaling dependency of this disease. These observations demonstrated that the manifestation and progression of systemic murine SAVI disease is dependent on various signaling pathways.</p><p>Murine SAVI is caused by heterozygous point mutations in <italic>Sting1</italic>, resulting in constitutive activation of STING with uncontrolled inflammatory activity. T cell lymphopenia and interstitial lung disease are characteristics of murine SAVI disease comparable to symptoms of severe COVID-19 disease. Cell fusion caused by SARS-CoV-2 spike protein is a potent activator of cGAS-STING pathway with induction of type I IFN and cytokine production (<xref ref-type="bibr" rid="bib7">Berthelot et al., 2020</xref>; <xref ref-type="bibr" rid="bib30">Liu et al., 2022b</xref>). During SARS-CoV-2 infection, the secretion of TNF and IFNγ induces inflammatory cell death by PANoptosis mediated by JAK/STAT1/IRF1 axis (<xref ref-type="bibr" rid="bib25">Karki et al., 2021</xref>). Infliximab treatment of patients with severe COVID-19 disease improved the numbers of blood CD4<sup>+</sup> T cells (<xref ref-type="bibr" rid="bib45">Popescu et al., 2022</xref>). The TNFR signaling is an essential part in the progression of COVID-19 disease as well as murine SAVI disease. Inhibition of TNFR activity is beneficial for both diseases.</p><p>In summary, our work suggests that TNFR1 signaling is a driver of murine SAVI disease. Loss of TNFR1 signaling can restore thymocyte (SP CD8 cells) numbers. Lack of TNFR1 signaling prevented the severe inflammatory lung disease manifestation in STING ki mice. However, it is important to note that with these newly generated mouse lines of TNFR signaling blockade, we are not able to explain all features of this systemic autoinflammatory disease. Additional investigations are required for complete elucidation of involved mechanisms and for development of new therapeutic options for SAVI patients.</p></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Supervision, Investigation, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Data curation, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Formal analysis, Investigation, Writing – original draft</p></fn><fn fn-type="con" id="con4"><p>Formal analysis, Investigation, Writing – original draft</p></fn><fn fn-type="con" id="con5"><p>Investigation</p></fn><fn fn-type="con" id="con6"><p>Data curation, Formal analysis, Investigation, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con7"><p>Formal analysis, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con8"><p>Investigation, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con9"><p>Investigation, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con10"><p>Investigation, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con11"><p>Data curation, Formal analysis, Investigation, Methodology, Writing – original draft</p></fn><fn fn-type="con" id="con12"><p>Formal analysis, Funding acquisition, Investigation, Writing – original draft</p></fn><fn fn-type="con" id="con13"><p>Data curation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Resources, Funding acquisition, Writing – original draft, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All mice experiments were approved by the Landesdirektion Sachsen (TVV 4/2019, TVV 13/2019) and carried out in accordance with the institutional guidelines on animal welfare.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>List of antibodies for FACS analysis (all from BioLegend).</title><p>The following antibodies were used for FACS analysis.</p></caption><media xlink:href="elife-101350-supp1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp2"><label>Supplementary file 2.</label><caption><title>List of antibodies for immunofluorescence staining of brain sections.</title><p>The following antibodies were used for staining of brain sections.</p></caption><media xlink:href="elife-101350-supp2-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp3"><label>Supplementary file 3.</label><caption><title>List of qRT-PCR primers.</title><p>The following primers were used for qRT-PCR analysis.</p></caption><media xlink:href="elife-101350-supp3-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="supp4"><label>Supplementary file 4<bold>.</bold></label><caption><title>List of effect size and power calculations.</title><p>Analysis of effect size and power were performed by G*Power 3.1.9.4, effect size d convention (&lt;0.5 = small, 0.5–0.8=medium, &gt;0.8 = large effect), and effect size f convention (&lt;0.25 = small, 0.25–0.4=medium, &gt;0.4 = large effect).</p></caption><media xlink:href="elife-101350-supp4-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-101350-mdarchecklist1-v2.docx" mimetype="application" mime-subtype="docx"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Transcriptomic data are deposited on GEO database, accession no GSE244062.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Behrendt</surname><given-names>R</given-names></name><name><surname>Luksch</surname><given-names>H</given-names></name><name><surname>Rösen-Wolff</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>Tissue-specific inflammation induced by constitutively active STING is mediated by enhanced TNF signaling</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE244062">GSE244062</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Katrin Höhne and Barbara Utess for excellent technical support. A Rösen-Wolff, LL Teichmann, C Günther, and R Behrendt were supported by the German Research Foundation (DFG) Project ID 369799452-TRR237. R Behrendt is additionally funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany’s Excellence Strategy – EXC2151-390873048.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anastasiou</surname><given-names>M</given-names></name><name><surname>Newton</surname><given-names>GA</given-names></name><name><surname>Kaur</surname><given-names>K</given-names></name><name><surname>Carrillo-Salinas</surname><given-names>FJ</given-names></name><name><surname>Smolgovsky</surname><given-names>SA</given-names></name><name><surname>Bayer</surname><given-names>AL</given-names></name><name><surname>Ilyukha</surname><given-names>V</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Poltorak</surname><given-names>A</given-names></name><name><surname>Luscinskas</surname><given-names>FW</given-names></name><name><surname>Alcaide</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Endothelial STING controls T cell transmigration in an IFNI-dependent manner</article-title><source>JCI Insight</source><volume>6</volume><elocation-id>e149346</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.149346</pub-id><pub-id pub-id-type="pmid">34156982</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atretkhany</surname><given-names>KSN</given-names></name><name><surname>Gogoleva</surname><given-names>VS</given-names></name><name><surname>Drutskaya</surname><given-names>MS</given-names></name><name><surname>Nedospasov</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Distinct modes of TNF signaling through its two receptors in health and disease</article-title><source>Journal of Leukocyte Biology</source><volume>107</volume><fpage>893</fpage><lpage>905</lpage><pub-id pub-id-type="doi">10.1002/JLB.2MR0120-510R</pub-id><pub-id pub-id-type="pmid">32083339</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Balka</surname><given-names>KR</given-names></name><name><surname>Louis</surname><given-names>C</given-names></name><name><surname>Saunders</surname><given-names>TL</given-names></name><name><surname>Smith</surname><given-names>AM</given-names></name><name><surname>Calleja</surname><given-names>DJ</given-names></name><name><surname>D’Silva</surname><given-names>DB</given-names></name><name><surname>Moghaddas</surname><given-names>F</given-names></name><name><surname>Tailler</surname><given-names>M</given-names></name><name><surname>Lawlor</surname><given-names>KE</given-names></name><name><surname>Zhan</surname><given-names>Y</given-names></name><name><surname>Burns</surname><given-names>CJ</given-names></name><name><surname>Wicks</surname><given-names>IP</given-names></name><name><surname>Miner</surname><given-names>JJ</given-names></name><name><surname>Kile</surname><given-names>BT</given-names></name><name><surname>Masters</surname><given-names>SL</given-names></name><name><surname>De Nardo</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>TBK1 and IKKε act redundantly to mediate STING-Induced NF-κB responses in myeloid cells</article-title><source>Cell Reports</source><volume>31</volume><elocation-id>107492</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.03.056</pub-id><pub-id pub-id-type="pmid">32268090</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Belhacéne</surname><given-names>N</given-names></name><name><surname>Gamas</surname><given-names>P</given-names></name><name><surname>Gonçalvès</surname><given-names>D</given-names></name><name><surname>Jacquin</surname><given-names>M</given-names></name><name><surname>Beneteau</surname><given-names>M</given-names></name><name><surname>Jacquel</surname><given-names>A</given-names></name><name><surname>Colosetti</surname><given-names>P</given-names></name><name><surname>Ricci</surname><given-names>JE</given-names></name><name><surname>Wakkach</surname><given-names>A</given-names></name><name><surname>Auberger</surname><given-names>P</given-names></name><name><surname>Marchetti</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Severe thymic atrophy in a mouse model of skin inflammation accounts for impaired TNFR1 signaling</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e47321</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0047321</pub-id><pub-id pub-id-type="pmid">23071785</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bennion</surname><given-names>BG</given-names></name><name><surname>Ingle</surname><given-names>H</given-names></name><name><surname>Ai</surname><given-names>TL</given-names></name><name><surname>Miner</surname><given-names>CA</given-names></name><name><surname>Platt</surname><given-names>DJ</given-names></name><name><surname>Smith</surname><given-names>AM</given-names></name><name><surname>Baldridge</surname><given-names>MT</given-names></name><name><surname>Miner</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A human gain-of-function STING mutation causes immunodeficiency and gammaherpesvirus-induced pulmonary fibrosis in mice</article-title><source>Journal of Virology</source><volume>93</volume><fpage>e01806</fpage><lpage>e01818</lpage><pub-id pub-id-type="doi">10.1128/JVI.01806-18</pub-id><pub-id pub-id-type="pmid">30463976</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bennion</surname><given-names>BG</given-names></name><name><surname>Croft</surname><given-names>CA</given-names></name><name><surname>Ai</surname><given-names>TL</given-names></name><name><surname>Qian</surname><given-names>W</given-names></name><name><surname>Menos</surname><given-names>AM</given-names></name><name><surname>Miner</surname><given-names>CA</given-names></name><name><surname>Frémond</surname><given-names>M-L</given-names></name><name><surname>Doisne</surname><given-names>J-M</given-names></name><name><surname>Andhey</surname><given-names>PS</given-names></name><name><surname>Platt</surname><given-names>DJ</given-names></name><name><surname>Bando</surname><given-names>JK</given-names></name><name><surname>Wang</surname><given-names>ER</given-names></name><name><surname>Luksch</surname><given-names>H</given-names></name><name><surname>Molina</surname><given-names>TJ</given-names></name><name><surname>Roberson</surname><given-names>EDO</given-names></name><name><surname>Artyomov</surname><given-names>MN</given-names></name><name><surname>Rösen-Wolff</surname><given-names>A</given-names></name><name><surname>Colonna</surname><given-names>M</given-names></name><name><surname>Rieux-Laucat</surname><given-names>F</given-names></name><name><surname>Di Santo</surname><given-names>JP</given-names></name><name><surname>Neven</surname><given-names>B</given-names></name><name><surname>Miner</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>STING Gain-of-function disrupts lymph node organogenesis and innate lymphoid cell development in mice</article-title><source>Cell Reports</source><volume>31</volume><elocation-id>107771</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2020.107771</pub-id><pub-id pub-id-type="pmid">32553167</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berthelot</surname><given-names>JM</given-names></name><name><surname>Lioté</surname><given-names>F</given-names></name><name><surname>Maugars</surname><given-names>Y</given-names></name><name><surname>Sibilia</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Lymphocyte changes in severe COVID-19: delayed over-activation of STING?</article-title><source>Frontiers in Immunology</source><volume>11</volume><elocation-id>607069</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.607069</pub-id><pub-id pub-id-type="pmid">33335532</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonville</surname><given-names>CA</given-names></name><name><surname>Percopo</surname><given-names>CM</given-names></name><name><surname>Dyer</surname><given-names>KD</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Prussin</surname><given-names>C</given-names></name><name><surname>Foster</surname><given-names>B</given-names></name><name><surname>Rosenberg</surname><given-names>HF</given-names></name><name><surname>Domachowske</surname><given-names>JB</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Interferon-gamma coordinates CCL3-mediated neutrophil recruitment in vivo</article-title><source>BMC Immunology</source><volume>10</volume><elocation-id>14</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2172-10-14</pub-id><pub-id pub-id-type="pmid">19298652</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Lin</surname><given-names>Z</given-names></name><name><surname>Xi</surname><given-names>L</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Differential role of TNFR1 and TNFR2 in the development of imiquimod-induced mouse psoriasis</article-title><source>Journal of Leukocyte Biology</source><volume>110</volume><fpage>1047</fpage><lpage>1055</lpage><pub-id pub-id-type="doi">10.1002/JLB.2MA0121-082R</pub-id><pub-id pub-id-type="pmid">34494306</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>K</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Luo</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Cytokine gene polymorphisms and parkinson’s disease: a meta-analysis</article-title><source>The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques</source><volume>39</volume><fpage>58</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1017/s0317167100012695</pub-id><pub-id pub-id-type="pmid">22384497</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clarke</surname><given-names>SLN</given-names></name><name><surname>Robertson</surname><given-names>L</given-names></name><name><surname>Rice</surname><given-names>GI</given-names></name><name><surname>Seabra</surname><given-names>L</given-names></name><name><surname>Hilliard</surname><given-names>TN</given-names></name><name><surname>Crow</surname><given-names>YJ</given-names></name><name><surname>Ramanan</surname><given-names>AV</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Type 1 interferonopathy presenting as juvenile idiopathic arthritis with interstitial lung disease: report of a new phenotype</article-title><source>Pediatric Rheumatology Online Journal</source><volume>18</volume><elocation-id>37</elocation-id><pub-id pub-id-type="doi">10.1186/s12969-020-00425-w</pub-id><pub-id pub-id-type="pmid">32398023</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Cevins</surname><given-names>C</given-names></name><name><surname>Delage</surname><given-names>L</given-names></name><name><surname>Batignes</surname><given-names>M</given-names></name><name><surname>Riller</surname><given-names>Q</given-names></name><name><surname>Luka</surname><given-names>M</given-names></name><name><surname>Remaury</surname><given-names>A</given-names></name><name><surname>Sorin</surname><given-names>B</given-names></name><name><surname>Fali</surname><given-names>T</given-names></name><name><surname>Masson</surname><given-names>C</given-names></name><name><surname>Hoareau</surname><given-names>B</given-names></name><name><surname>Meunier</surname><given-names>C</given-names></name><name><surname>Parisot</surname><given-names>M</given-names></name><name><surname>Zarhrate</surname><given-names>M</given-names></name><name><surname>Pérot</surname><given-names>BP</given-names></name><name><surname>García-Paredes</surname><given-names>V</given-names></name><name><surname>Carbone</surname><given-names>F</given-names></name><name><surname>Galliot</surname><given-names>L</given-names></name><name><surname>Nal</surname><given-names>B</given-names></name><name><surname>Pierre</surname><given-names>P</given-names></name><name><surname>Canard</surname><given-names>L</given-names></name><name><surname>Boussard</surname><given-names>C</given-names></name><name><surname>Crickx</surname><given-names>E</given-names></name><name><surname>Guillemot</surname><given-names>JC</given-names></name><name><surname>Bader-Meunier</surname><given-names>B</given-names></name><name><surname>Bélot</surname><given-names>A</given-names></name><name><surname>Quartier</surname><given-names>P</given-names></name><name><surname>Frémond</surname><given-names>ML</given-names></name><name><surname>Neven</surname><given-names>B</given-names></name><name><surname>Boldina</surname><given-names>G</given-names></name><name><surname>Augé</surname><given-names>F</given-names></name><name><surname>Alain</surname><given-names>F</given-names></name><name><surname>Didier</surname><given-names>M</given-names></name><name><surname>Rieux-Laucat</surname><given-names>F</given-names></name><name><surname>Ménager</surname><given-names>MM</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Single-cell RNA-sequencing of PBMCs from SAVI patients reveals disease-associated monocytes with elevated integrated stress response</article-title><source>Cell Reports. Medicine</source><volume>4</volume><elocation-id>101333</elocation-id><pub-id pub-id-type="doi">10.1016/j.xcrm.2023.101333</pub-id><pub-id pub-id-type="pmid">38118407</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>Z</given-names></name><name><surname>Chong</surname><given-names>Z</given-names></name><name><surname>Law</surname><given-names>CS</given-names></name><name><surname>Mukai</surname><given-names>K</given-names></name><name><surname>Ho</surname><given-names>FO</given-names></name><name><surname>Martinu</surname><given-names>T</given-names></name><name><surname>Backes</surname><given-names>BJ</given-names></name><name><surname>Eckalbar</surname><given-names>WL</given-names></name><name><surname>Taguchi</surname><given-names>T</given-names></name><name><surname>Shum</surname><given-names>AK</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A defect in COPI-mediated transport of STING causes immune dysregulation in COPA syndrome</article-title><source>The Journal of Experimental Medicine</source><volume>217</volume><elocation-id>e20201045</elocation-id><pub-id pub-id-type="doi">10.1084/jem.20201045</pub-id><pub-id pub-id-type="pmid">32725126</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Oliveira Mann</surname><given-names>CC</given-names></name><name><surname>Orzalli</surname><given-names>MH</given-names></name><name><surname>King</surname><given-names>DS</given-names></name><name><surname>Kagan</surname><given-names>JC</given-names></name><name><surname>Lee</surname><given-names>ASY</given-names></name><name><surname>Kranzusch</surname><given-names>PJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Modular architecture of the STING C-terminal tail allows interferon and NF-κB signaling adaptation</article-title><source>Cell Reports</source><volume>27</volume><fpage>1165</fpage><lpage>1175</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.03.098</pub-id><pub-id pub-id-type="pmid">31018131</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Domizio</surname><given-names>JD</given-names></name><name><surname>Gulen</surname><given-names>MF</given-names></name><name><surname>Saidoune</surname><given-names>F</given-names></name><name><surname>Thacker</surname><given-names>VV</given-names></name><name><surname>Yatim</surname><given-names>A</given-names></name><name><surname>Sharma</surname><given-names>K</given-names></name><name><surname>Nass</surname><given-names>T</given-names></name><name><surname>Guenova</surname><given-names>E</given-names></name><name><surname>Schaller</surname><given-names>M</given-names></name><name><surname>Conrad</surname><given-names>C</given-names></name><name><surname>Goepfert</surname><given-names>C</given-names></name><name><surname>de Leval</surname><given-names>L</given-names></name><name><surname>von Garnier</surname><given-names>C</given-names></name><name><surname>Berezowska</surname><given-names>S</given-names></name><name><surname>Dubois</surname><given-names>A</given-names></name><name><surname>Gilliet</surname><given-names>M</given-names></name><name><surname>Ablasser</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The cGAS-STING pathway drives type I IFN immunopathology in COVID-19</article-title><source>Nature</source><volume>603</volume><fpage>145</fpage><lpage>151</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-04421-w</pub-id><pub-id pub-id-type="pmid">35045565</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Erickson</surname><given-names>SL</given-names></name><name><surname>de Sauvage</surname><given-names>FJ</given-names></name><name><surname>Kikly</surname><given-names>K</given-names></name><name><surname>Carver-Moore</surname><given-names>K</given-names></name><name><surname>Pitts-Meek</surname><given-names>S</given-names></name><name><surname>Gillett</surname><given-names>N</given-names></name><name><surname>Sheehan</surname><given-names>KC</given-names></name><name><surname>Schreiber</surname><given-names>RD</given-names></name><name><surname>Goeddel</surname><given-names>DV</given-names></name><name><surname>Moore</surname><given-names>MW</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Decreased sensitivity to tumour-necrosis factor but normal T-cell development in TNF receptor-2-deficient mice</article-title><source>Nature</source><volume>372</volume><fpage>560</fpage><lpage>563</lpage><pub-id pub-id-type="doi">10.1038/372560a0</pub-id><pub-id pub-id-type="pmid">7990930</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fehrenbach</surname><given-names>ML</given-names></name><name><surname>Cao</surname><given-names>G</given-names></name><name><surname>Williams</surname><given-names>JT</given-names></name><name><surname>Finklestein</surname><given-names>JM</given-names></name><name><surname>Delisser</surname><given-names>HM</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Isolation of murine lung endothelial cells</article-title><source>American Journal of Physiology. Lung Cellular and Molecular Physiology</source><volume>296</volume><fpage>L1096</fpage><lpage>L1103</lpage><pub-id pub-id-type="doi">10.1152/ajplung.90613.2008</pub-id><pub-id pub-id-type="pmid">19304908</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>KM</given-names></name><name><surname>Motwani</surname><given-names>M</given-names></name><name><surname>Tedder</surname><given-names>T</given-names></name><name><surname>Marshak-Rothstein</surname><given-names>A</given-names></name><name><surname>Fitzgerald</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Radioresistant cells initiate lymphocyte-dependent lung inflammation and IFNγ-dependent mortality in STING gain-of-function mice</article-title><source>PNAS</source><volume>119</volume><elocation-id>e2202327119</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2202327119</pub-id><pub-id pub-id-type="pmid">35696583</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>KM</given-names></name><name><surname>Chiang</surname><given-names>K</given-names></name><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Korkmaz</surname><given-names>FT</given-names></name><name><surname>Janardhan</surname><given-names>HP</given-names></name><name><surname>Trivedi</surname><given-names>CM</given-names></name><name><surname>Quinton</surname><given-names>LJ</given-names></name><name><surname>Gingras</surname><given-names>S</given-names></name><name><surname>Fitzgerald</surname><given-names>KA</given-names></name><name><surname>Marshak-Rothstein</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Endothelial cell expression of a STING gain-of-function mutation initiates pulmonary lymphocytic infiltration</article-title><source>Cell Reports</source><volume>43</volume><elocation-id>114114</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2024.114114</pub-id><pub-id pub-id-type="pmid">38625791</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gonugunta</surname><given-names>VK</given-names></name><name><surname>Sakai</surname><given-names>T</given-names></name><name><surname>Pokatayev</surname><given-names>V</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Dobbs</surname><given-names>N</given-names></name><name><surname>Yan</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Trafficking-mediated STING degradation requires sorting to acidified endolysosomes and can be targeted to enhance anti-tumor response</article-title><source>Cell Reports</source><volume>21</volume><fpage>3234</fpage><lpage>3242</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.11.061</pub-id><pub-id pub-id-type="pmid">29241549</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harms</surname><given-names>AS</given-names></name><name><surname>Ferreira</surname><given-names>SA</given-names></name><name><surname>Romero-Ramos</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Periphery and brain, innate and adaptive immunity in Parkinson’s disease</article-title><source>Acta Neuropathologica</source><volume>141</volume><fpage>527</fpage><lpage>545</lpage><pub-id pub-id-type="doi">10.1007/s00401-021-02268-5</pub-id><pub-id pub-id-type="pmid">33555429</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrell</surname><given-names>MI</given-names></name><name><surname>Iritani</surname><given-names>BM</given-names></name><name><surname>Ruddell</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Lymph node mapping in the mouse</article-title><source>Journal of Immunological Methods</source><volume>332</volume><fpage>170</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1016/j.jim.2007.11.012</pub-id><pub-id pub-id-type="pmid">18164026</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hinkle</surname><given-names>JT</given-names></name><name><surname>Patel</surname><given-names>J</given-names></name><name><surname>Panicker</surname><given-names>N</given-names></name><name><surname>Karuppagounder</surname><given-names>SS</given-names></name><name><surname>Biswas</surname><given-names>D</given-names></name><name><surname>Belingon</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>R</given-names></name><name><surname>Brahmachari</surname><given-names>S</given-names></name><name><surname>Pletnikova</surname><given-names>O</given-names></name><name><surname>Troncoso</surname><given-names>JC</given-names></name><name><surname>Dawson</surname><given-names>VL</given-names></name><name><surname>Dawson</surname><given-names>TM</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>STING mediates neurodegeneration and neuroinflammation in nigrostriatal α-synucleinopathy</article-title><source>PNAS</source><volume>119</volume><elocation-id>e2118819119</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2118819119</pub-id><pub-id pub-id-type="pmid">35394877</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hopfner</surname><given-names>KP</given-names></name><name><surname>Hornung</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Molecular mechanisms and cellular functions of cGAS-STING signalling</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>21</volume><fpage>501</fpage><lpage>521</lpage><pub-id pub-id-type="doi">10.1038/s41580-020-0244-x</pub-id><pub-id pub-id-type="pmid">32424334</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karki</surname><given-names>R</given-names></name><name><surname>Sharma</surname><given-names>BR</given-names></name><name><surname>Tuladhar</surname><given-names>S</given-names></name><name><surname>Williams</surname><given-names>EP</given-names></name><name><surname>Zalduondo</surname><given-names>L</given-names></name><name><surname>Samir</surname><given-names>P</given-names></name><name><surname>Zheng</surname><given-names>M</given-names></name><name><surname>Sundaram</surname><given-names>B</given-names></name><name><surname>Banoth</surname><given-names>B</given-names></name><name><surname>Malireddi</surname><given-names>RKS</given-names></name><name><surname>Schreiner</surname><given-names>P</given-names></name><name><surname>Neale</surname><given-names>G</given-names></name><name><surname>Vogel</surname><given-names>P</given-names></name><name><surname>Webby</surname><given-names>R</given-names></name><name><surname>Jonsson</surname><given-names>CB</given-names></name><name><surname>Kanneganti</surname><given-names>TD</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Synergism of TNF-α and IFN-γ triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes</article-title><source>Cell</source><volume>184</volume><fpage>149</fpage><lpage>168</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2020.11.025</pub-id><pub-id pub-id-type="pmid">33278357</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kessler</surname><given-names>N</given-names></name><name><surname>Viehmann</surname><given-names>SF</given-names></name><name><surname>Krollmann</surname><given-names>C</given-names></name><name><surname>Mai</surname><given-names>K</given-names></name><name><surname>Kirschner</surname><given-names>KM</given-names></name><name><surname>Luksch</surname><given-names>H</given-names></name><name><surname>Kotagiri</surname><given-names>P</given-names></name><name><surname>Böhner</surname><given-names>AMC</given-names></name><name><surname>Huugen</surname><given-names>D</given-names></name><name><surname>de Oliveira Mann</surname><given-names>CC</given-names></name><name><surname>Otten</surname><given-names>S</given-names></name><name><surname>Weiss</surname><given-names>SAI</given-names></name><name><surname>Zillinger</surname><given-names>T</given-names></name><name><surname>Dobrikova</surname><given-names>K</given-names></name><name><surname>Jenne</surname><given-names>DE</given-names></name><name><surname>Behrendt</surname><given-names>R</given-names></name><name><surname>Ablasser</surname><given-names>A</given-names></name><name><surname>Bartok</surname><given-names>E</given-names></name><name><surname>Hartmann</surname><given-names>G</given-names></name><name><surname>Hopfner</surname><given-names>K-P</given-names></name><name><surname>Lyons</surname><given-names>PA</given-names></name><name><surname>Boor</surname><given-names>P</given-names></name><name><surname>Rösen-Wolff</surname><given-names>A</given-names></name><name><surname>Teichmann</surname><given-names>LL</given-names></name><name><surname>Heeringa</surname><given-names>P</given-names></name><name><surname>Kurts</surname><given-names>C</given-names></name><name><surname>Garbi</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Monocyte-derived macrophages aggravate pulmonary vasculitis via cGAS/STING/IFN-mediated nucleic acid sensing</article-title><source>The Journal of Experimental Medicine</source><volume>219</volume><elocation-id>e20220759</elocation-id><pub-id pub-id-type="doi">10.1084/jem.20220759</pub-id><pub-id pub-id-type="pmid">35997679</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Fisher</surname><given-names>J</given-names></name><name><surname>Gonzales</surname><given-names>C</given-names></name><name><surname>Trent</surname><given-names>B</given-names></name><name><surname>Card</surname><given-names>G</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Tumanov</surname><given-names>AV</given-names></name><name><surname>Soong</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Distinct Role of TNFR1 and TNFR2 in protective immunity against orientia tsutsugamushi infection in mice</article-title><source>Frontiers in Immunology</source><volume>13</volume><elocation-id>867924</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2022.867924</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Jesus</surname><given-names>AA</given-names></name><name><surname>Marrero</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Ramsey</surname><given-names>SE</given-names></name><name><surname>Sanchez</surname><given-names>GAM</given-names></name><name><surname>Tenbrock</surname><given-names>K</given-names></name><name><surname>Wittkowski</surname><given-names>H</given-names></name><name><surname>Jones</surname><given-names>OY</given-names></name><name><surname>Kuehn</surname><given-names>HS</given-names></name><name><surname>Lee</surname><given-names>C-CR</given-names></name><name><surname>DiMattia</surname><given-names>MA</given-names></name><name><surname>Cowen</surname><given-names>EW</given-names></name><name><surname>Gonzalez</surname><given-names>B</given-names></name><name><surname>Palmer</surname><given-names>I</given-names></name><name><surname>DiGiovanna</surname><given-names>JJ</given-names></name><name><surname>Biancotto</surname><given-names>A</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Tsai</surname><given-names>WL</given-names></name><name><surname>Trier</surname><given-names>AM</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Stone</surname><given-names>DL</given-names></name><name><surname>Hill</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>HJ</given-names></name><name><surname>St Hilaire</surname><given-names>C</given-names></name><name><surname>Gurprasad</surname><given-names>S</given-names></name><name><surname>Plass</surname><given-names>N</given-names></name><name><surname>Chapelle</surname><given-names>D</given-names></name><name><surname>Horkayne-Szakaly</surname><given-names>I</given-names></name><name><surname>Foell</surname><given-names>D</given-names></name><name><surname>Barysenka</surname><given-names>A</given-names></name><name><surname>Candotti</surname><given-names>F</given-names></name><name><surname>Holland</surname><given-names>SM</given-names></name><name><surname>Hughes</surname><given-names>JD</given-names></name><name><surname>Mehmet</surname><given-names>H</given-names></name><name><surname>Issekutz</surname><given-names>AC</given-names></name><name><surname>Raffeld</surname><given-names>M</given-names></name><name><surname>McElwee</surname><given-names>J</given-names></name><name><surname>Fontana</surname><given-names>JR</given-names></name><name><surname>Minniti</surname><given-names>CP</given-names></name><name><surname>Moir</surname><given-names>S</given-names></name><name><surname>Kastner</surname><given-names>DL</given-names></name><name><surname>Gadina</surname><given-names>M</given-names></name><name><surname>Steven</surname><given-names>AC</given-names></name><name><surname>Wingfield</surname><given-names>PT</given-names></name><name><surname>Brooks</surname><given-names>SR</given-names></name><name><surname>Rosenzweig</surname><given-names>SD</given-names></name><name><surname>Fleisher</surname><given-names>TA</given-names></name><name><surname>Deng</surname><given-names>Z</given-names></name><name><surname>Boehm</surname><given-names>M</given-names></name><name><surname>Paller</surname><given-names>AS</given-names></name><name><surname>Goldbach-Mansky</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Activated STING in a vascular and pulmonary syndrome</article-title><source>The New England Journal of Medicine</source><volume>371</volume><fpage>507</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1312625</pub-id><pub-id pub-id-type="pmid">25029335</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Wei</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>F</given-names></name><name><surname>Zhao</surname><given-names>F</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Fan</surname><given-names>Z</given-names></name><name><surname>Mei</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Zhai</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>A</given-names></name><name><surname>Cen</surname><given-names>S</given-names></name><name><surname>Liang</surname><given-names>C</given-names></name><name><surname>Guo</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2022">2022a</year><article-title>SARS-CoV-2 spike protein-induced cell fusion activates the cGAS-STING pathway and the interferon response</article-title><source>Science Signaling</source><volume>15</volume><elocation-id>eabg8744</elocation-id><pub-id pub-id-type="doi">10.1126/scisignal.abg8744</pub-id><pub-id pub-id-type="pmid">35412852</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>P</given-names></name><name><surname>Rivara</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Ricci</surname><given-names>J</given-names></name><name><surname>Ren</surname><given-names>X</given-names></name><name><surname>Hurley</surname><given-names>JH</given-names></name><name><surname>Ablasser</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2022">2022b</year><article-title>Clathrin-associated AP-1 controls termination of STING signalling</article-title><source>Nature</source><volume>610</volume><fpage>761</fpage><lpage>767</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-05354-0</pub-id><pub-id pub-id-type="pmid">36261523</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Love</surname><given-names>MI</given-names></name><name><surname>Huber</surname><given-names>W</given-names></name><name><surname>Anders</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2</article-title><source>Genome Biology</source><volume>15</volume><elocation-id>550</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-014-0550-8</pub-id><pub-id pub-id-type="pmid">25516281</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luksch</surname><given-names>H</given-names></name><name><surname>Stinson</surname><given-names>WA</given-names></name><name><surname>Platt</surname><given-names>DJ</given-names></name><name><surname>Qian</surname><given-names>W</given-names></name><name><surname>Kalugotla</surname><given-names>G</given-names></name><name><surname>Miner</surname><given-names>CA</given-names></name><name><surname>Bennion</surname><given-names>BG</given-names></name><name><surname>Gerbaulet</surname><given-names>A</given-names></name><name><surname>Rösen-Wolff</surname><given-names>A</given-names></name><name><surname>Miner</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>STING-associated lung disease in mice relies on T cells but not type I interferon</article-title><source>The Journal of Allergy and Clinical Immunology</source><volume>144</volume><fpage>254</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1016/j.jaci.2019.01.044</pub-id><pub-id pub-id-type="pmid">30772497</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacLauchlan</surname><given-names>S</given-names></name><name><surname>Kushwaha</surname><given-names>P</given-names></name><name><surname>Tai</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Manning</surname><given-names>C</given-names></name><name><surname>Swarnkar</surname><given-names>G</given-names></name><name><surname>Abu-Amer</surname><given-names>Y</given-names></name><name><surname>Fitzgerald</surname><given-names>KA</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Gravallese</surname><given-names>EM</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>STING-dependent interferon signatures restrict osteoclast differentiation and bone loss in mice</article-title><source>PNAS</source><volume>120</volume><elocation-id>e2210409120</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.2210409120</pub-id><pub-id pub-id-type="pmid">37023130</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>GR</given-names></name><name><surname>Henare</surname><given-names>K</given-names></name><name><surname>Salazar</surname><given-names>C</given-names></name><name><surname>Scheidl-Yee</surname><given-names>T</given-names></name><name><surname>Eggen</surname><given-names>LJ</given-names></name><name><surname>Tailor</surname><given-names>PP</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Podstawka</surname><given-names>J</given-names></name><name><surname>Fritzler</surname><given-names>MJ</given-names></name><name><surname>Kelly</surname><given-names>MM</given-names></name><name><surname>Yipp</surname><given-names>BG</given-names></name><name><surname>Jirik</surname><given-names>FR</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Expression of a constitutively active human <italic>STING</italic> mutant in hematopoietic cells produces an <italic>Ifnar1</italic>-dependent vasculopathy in mice</article-title><source>Life Science Alliance</source><volume>2</volume><elocation-id>e201800215</elocation-id><pub-id pub-id-type="doi">10.26508/lsa.201800215</pub-id><pub-id pub-id-type="pmid">31221625</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McFarlane</surname><given-names>SM</given-names></name><name><surname>Pashmi</surname><given-names>G</given-names></name><name><surname>Connell</surname><given-names>MC</given-names></name><name><surname>Littlejohn</surname><given-names>AF</given-names></name><name><surname>Tucker</surname><given-names>SJ</given-names></name><name><surname>Vandenabeele</surname><given-names>P</given-names></name><name><surname>MacEwan</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Differential activation of nuclear factor-kappaB by tumour necrosis factor receptor subtypes: TNFR1 predominates whereas TNFR2 activates transcription poorly</article-title><source>FEBS Letters</source><volume>515</volume><fpage>119</fpage><lpage>126</lpage><pub-id pub-id-type="doi">10.1016/s0014-5793(02)02450-x</pub-id><pub-id pub-id-type="pmid">11943206</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mercer</surname><given-names>PF</given-names></name><name><surname>Williams</surname><given-names>AE</given-names></name><name><surname>Scotton</surname><given-names>CJ</given-names></name><name><surname>José</surname><given-names>RJ</given-names></name><name><surname>Sulikowski</surname><given-names>M</given-names></name><name><surname>Moffatt</surname><given-names>JD</given-names></name><name><surname>Murray</surname><given-names>LA</given-names></name><name><surname>Chambers</surname><given-names>RC</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Proteinase-activated receptor-1, CCL2, and CCL7 regulate acute neutrophilic lung inflammation</article-title><source>American Journal of Respiratory Cell and Molecular Biology</source><volume>50</volume><fpage>144</fpage><lpage>157</lpage><pub-id pub-id-type="doi">10.1165/rcmb.2013-0142OC</pub-id><pub-id pub-id-type="pmid">23972264</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Motwani</surname><given-names>M</given-names></name><name><surname>Pawaria</surname><given-names>S</given-names></name><name><surname>Bernier</surname><given-names>J</given-names></name><name><surname>Moses</surname><given-names>S</given-names></name><name><surname>Henry</surname><given-names>K</given-names></name><name><surname>Fang</surname><given-names>T</given-names></name><name><surname>Burkly</surname><given-names>L</given-names></name><name><surname>Marshak-Rothstein</surname><given-names>A</given-names></name><name><surname>Fitzgerald</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Hierarchy of clinical manifestations in SAVI N153S and V154M mouse models</article-title><source>PNAS</source><volume>116</volume><fpage>7941</fpage><lpage>7950</lpage><pub-id pub-id-type="doi">10.1073/pnas.1818281116</pub-id><pub-id pub-id-type="pmid">30944222</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mulay</surname><given-names>SR</given-names></name><name><surname>Eberhard</surname><given-names>JN</given-names></name><name><surname>Desai</surname><given-names>J</given-names></name><name><surname>Marschner</surname><given-names>JA</given-names></name><name><surname>Kumar</surname><given-names>SVR</given-names></name><name><surname>Weidenbusch</surname><given-names>M</given-names></name><name><surname>Grigorescu</surname><given-names>M</given-names></name><name><surname>Lech</surname><given-names>M</given-names></name><name><surname>Eltrich</surname><given-names>N</given-names></name><name><surname>Müller</surname><given-names>L</given-names></name><name><surname>Hans</surname><given-names>W</given-names></name><name><surname>Hrabě de Angelis</surname><given-names>M</given-names></name><name><surname>Vielhauer</surname><given-names>V</given-names></name><name><surname>Hoppe</surname><given-names>B</given-names></name><name><surname>Asplin</surname><given-names>J</given-names></name><name><surname>Burzlaff</surname><given-names>N</given-names></name><name><surname>Herrmann</surname><given-names>M</given-names></name><name><surname>Evan</surname><given-names>A</given-names></name><name><surname>Anders</surname><given-names>H-J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Hyperoxaluria Requires TNF receptors to initiate crystal adhesion and kidney stone disease</article-title><source>Journal of the American Society of Nephrology</source><volume>28</volume><fpage>761</fpage><lpage>768</lpage><pub-id pub-id-type="doi">10.1681/ASN.2016040486</pub-id><pub-id pub-id-type="pmid">27612997</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishimura</surname><given-names>M</given-names></name><name><surname>Mizuta</surname><given-names>I</given-names></name><name><surname>Mizuta</surname><given-names>E</given-names></name><name><surname>Yamasaki</surname><given-names>S</given-names></name><name><surname>Ohta</surname><given-names>M</given-names></name><name><surname>Kaji</surname><given-names>R</given-names></name><name><surname>Kuno</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Tumor necrosis factor gene polymorphisms in patients with sporadic Parkinson’s disease</article-title><source>Neuroscience Letters</source><volume>311</volume><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/s0304-3940(01)02111-5</pub-id><pub-id pub-id-type="pmid">11585553</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peschon</surname><given-names>JJ</given-names></name><name><surname>Torrance</surname><given-names>DS</given-names></name><name><surname>Stocking</surname><given-names>KL</given-names></name><name><surname>Glaccum</surname><given-names>MB</given-names></name><name><surname>Otten</surname><given-names>C</given-names></name><name><surname>Willis</surname><given-names>CR</given-names></name><name><surname>Charrier</surname><given-names>K</given-names></name><name><surname>Morrissey</surname><given-names>PJ</given-names></name><name><surname>Ware</surname><given-names>CB</given-names></name><name><surname>Mohler</surname><given-names>KM</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation</article-title><source>Journal of Immunology</source><volume>160</volume><fpage>943</fpage><lpage>952</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.160.2.943</pub-id><pub-id pub-id-type="pmid">9551933</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peter</surname><given-names>I</given-names></name><name><surname>Dubinsky</surname><given-names>M</given-names></name><name><surname>Bressman</surname><given-names>S</given-names></name><name><surname>Park</surname><given-names>A</given-names></name><name><surname>Lu</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Anti-tumor necrosis factor therapy and incidence of parkinson disease among patients with inflammatory bowel disease</article-title><source>JAMA Neurology</source><volume>75</volume><fpage>939</fpage><lpage>946</lpage><pub-id pub-id-type="doi">10.1001/jamaneurol.2018.0605</pub-id><pub-id pub-id-type="pmid">29710331</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfeffer</surname><given-names>K</given-names></name><name><surname>Matsuyama</surname><given-names>T</given-names></name><name><surname>Kündig</surname><given-names>TM</given-names></name><name><surname>Wakeham</surname><given-names>A</given-names></name><name><surname>Kishihara</surname><given-names>K</given-names></name><name><surname>Shahinian</surname><given-names>A</given-names></name><name><surname>Wiegmann</surname><given-names>K</given-names></name><name><surname>Ohashi</surname><given-names>PS</given-names></name><name><surname>Krönke</surname><given-names>M</given-names></name><name><surname>Mak</surname><given-names>TW</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection</article-title><source>Cell</source><volume>73</volume><fpage>457</fpage><lpage>467</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(93)90134-c</pub-id><pub-id pub-id-type="pmid">8387893</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Picard</surname><given-names>C</given-names></name><name><surname>Thouvenin</surname><given-names>G</given-names></name><name><surname>Kannengiesser</surname><given-names>C</given-names></name><name><surname>Dubus</surname><given-names>JC</given-names></name><name><surname>Jeremiah</surname><given-names>N</given-names></name><name><surname>Rieux-Laucat</surname><given-names>F</given-names></name><name><surname>Crestani</surname><given-names>B</given-names></name><name><surname>Belot</surname><given-names>A</given-names></name><name><surname>Thivolet-Béjui</surname><given-names>F</given-names></name><name><surname>Secq</surname><given-names>V</given-names></name><name><surname>Ménard</surname><given-names>C</given-names></name><name><surname>Reynaud-Gaubert</surname><given-names>M</given-names></name><name><surname>Reix</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Severe pulmonary fibrosis as the first manifestation of interferonopathy (TMEM173 Mutation)</article-title><source>Chest</source><volume>150</volume><fpage>e65</fpage><lpage>e71</lpage><pub-id pub-id-type="doi">10.1016/j.chest.2016.02.682</pub-id><pub-id pub-id-type="pmid">27613991</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Platt</surname><given-names>DJ</given-names></name><name><surname>Lawrence</surname><given-names>D</given-names></name><name><surname>Rodgers</surname><given-names>R</given-names></name><name><surname>Schriefer</surname><given-names>L</given-names></name><name><surname>Qian</surname><given-names>W</given-names></name><name><surname>Miner</surname><given-names>CA</given-names></name><name><surname>Menos</surname><given-names>AM</given-names></name><name><surname>Kennedy</surname><given-names>EA</given-names></name><name><surname>Peterson</surname><given-names>ST</given-names></name><name><surname>Stinson</surname><given-names>WA</given-names></name><name><surname>Baldridge</surname><given-names>MT</given-names></name><name><surname>Miner</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Transferrable protection by gut microbes against STING-associated lung disease</article-title><source>Cell Reports</source><volume>35</volume><elocation-id>109113</elocation-id><pub-id pub-id-type="doi">10.1016/j.celrep.2021.109113</pub-id><pub-id pub-id-type="pmid">33979608</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Popescu</surname><given-names>I</given-names></name><name><surname>Snyder</surname><given-names>ME</given-names></name><name><surname>Iasella</surname><given-names>CJ</given-names></name><name><surname>Hannan</surname><given-names>SJ</given-names></name><name><surname>Koshy</surname><given-names>R</given-names></name><name><surname>Burke</surname><given-names>R</given-names></name><name><surname>Das</surname><given-names>A</given-names></name><name><surname>Brown</surname><given-names>MJ</given-names></name><name><surname>Lyons</surname><given-names>EJ</given-names></name><name><surname>Lieber</surname><given-names>SC</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Sembrat</surname><given-names>JC</given-names></name><name><surname>Bhatt</surname><given-names>P</given-names></name><name><surname>Deng</surname><given-names>E</given-names></name><name><surname>An</surname><given-names>X</given-names></name><name><surname>Linstrum</surname><given-names>K</given-names></name><name><surname>Kitsios</surname><given-names>G</given-names></name><name><surname>Konstantinidis</surname><given-names>I</given-names></name><name><surname>Saul</surname><given-names>M</given-names></name><name><surname>Kass</surname><given-names>DJ</given-names></name><name><surname>Alder</surname><given-names>JK</given-names></name><name><surname>Chen</surname><given-names>BB</given-names></name><name><surname>Lendermon</surname><given-names>EA</given-names></name><name><surname>Kilaru</surname><given-names>S</given-names></name><name><surname>Johnson</surname><given-names>B</given-names></name><name><surname>Pilewski</surname><given-names>JM</given-names></name><name><surname>Kiss</surname><given-names>JE</given-names></name><name><surname>Wells</surname><given-names>AH</given-names></name><name><surname>Morris</surname><given-names>A</given-names></name><name><surname>McVerry</surname><given-names>BJ</given-names></name><name><surname>McMahon</surname><given-names>DK</given-names></name><name><surname>Triulzi</surname><given-names>DJ</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Sanchez</surname><given-names>PG</given-names></name><name><surname>McDyer</surname><given-names>JF</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>CD4<sup>+</sup> T-cell dysfunction in severe COVID-19 disease is tumor necrosis factor-α/tumor necrosis factor receptor 1-dependent</article-title><source>American Journal of Respiratory and Critical Care Medicine</source><volume>205</volume><fpage>1403</fpage><lpage>1418</lpage><pub-id pub-id-type="doi">10.1164/rccm.202111-2493OC</pub-id><pub-id pub-id-type="pmid">35348444</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhead</surname><given-names>B</given-names></name><name><surname>Shao</surname><given-names>X</given-names></name><name><surname>Quach</surname><given-names>H</given-names></name><name><surname>Ghai</surname><given-names>P</given-names></name><name><surname>Barcellos</surname><given-names>LF</given-names></name><name><surname>Bowcock</surname><given-names>AM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Global expression and CpG methylation analysis of primary endothelial cells before and after TNFa stimulation reveals gene modules enriched in inflammatory and infectious diseases and associated DMRs</article-title><source>PLOS ONE</source><volume>15</volume><elocation-id>e0230884</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0230884</pub-id><pub-id pub-id-type="pmid">32231389</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roblek</surname><given-names>M</given-names></name><name><surname>Protsyuk</surname><given-names>D</given-names></name><name><surname>Becker</surname><given-names>PF</given-names></name><name><surname>Stefanescu</surname><given-names>C</given-names></name><name><surname>Gorzelanny</surname><given-names>C</given-names></name><name><surname>Glaus Garzon</surname><given-names>JF</given-names></name><name><surname>Knopfova</surname><given-names>L</given-names></name><name><surname>Heikenwalder</surname><given-names>M</given-names></name><name><surname>Luckow</surname><given-names>B</given-names></name><name><surname>Schneider</surname><given-names>SW</given-names></name><name><surname>Borsig</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>CCL2 Is a vascular permeability factor inducing ccr2-dependent endothelial retraction during lung metastasis</article-title><source>Molecular Cancer Research</source><volume>17</volume><fpage>783</fpage><lpage>793</lpage><pub-id pub-id-type="doi">10.1158/1541-7786.MCR-18-0530</pub-id><pub-id pub-id-type="pmid">30552233</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>D</given-names></name><name><surname>Malik</surname><given-names>A</given-names></name><name><surname>Guy</surname><given-names>C</given-names></name><name><surname>Vogel</surname><given-names>P</given-names></name><name><surname>Kanneganti</surname><given-names>TD</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>TNF/TNFR axis promotes pyrin inflammasome activation and distinctly modulates pyrin inflammasomopathy</article-title><source>The Journal of Clinical Investigation</source><volume>129</volume><fpage>150</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1172/JCI121372</pub-id><pub-id pub-id-type="pmid">30457980</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shmuel-Galia</surname><given-names>L</given-names></name><name><surname>Humphries</surname><given-names>F</given-names></name><name><surname>Lei</surname><given-names>X</given-names></name><name><surname>Ceglia</surname><given-names>S</given-names></name><name><surname>Wilson</surname><given-names>R</given-names></name><name><surname>Jiang</surname><given-names>Z</given-names></name><name><surname>Ketelut-Carneiro</surname><given-names>N</given-names></name><name><surname>Foley</surname><given-names>SE</given-names></name><name><surname>Pechhold</surname><given-names>S</given-names></name><name><surname>Houghton</surname><given-names>J</given-names></name><name><surname>Muneeruddin</surname><given-names>K</given-names></name><name><surname>Shaffer</surname><given-names>SA</given-names></name><name><surname>McCormick</surname><given-names>BA</given-names></name><name><surname>Reboldi</surname><given-names>A</given-names></name><name><surname>Ward</surname><given-names>D</given-names></name><name><surname>Marshak-Rothstein</surname><given-names>A</given-names></name><name><surname>Fitzgerald</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Dysbiosis exacerbates colitis by promoting ubiquitination and accumulation of the innate immune adaptor STING in myeloid cells</article-title><source>Immunity</source><volume>54</volume><fpage>1137</fpage><lpage>1153</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2021.05.008</pub-id><pub-id pub-id-type="pmid">34051146</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siedel</surname><given-names>H</given-names></name><name><surname>Roers</surname><given-names>A</given-names></name><name><surname>Rösen-Wolff</surname><given-names>A</given-names></name><name><surname>Luksch</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Type I interferon-independent T cell impairment in a Tmem173 N153S/WT mouse model of STING associated vasculopathy with onset in infancy (SAVI)</article-title><source>Clinical Immunology</source><volume>216</volume><elocation-id>108466</elocation-id><pub-id pub-id-type="doi">10.1016/j.clim.2020.108466</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spandidos</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Seed</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>PrimerBank: a resource of human and mouse PCR primer pairs for gene expression detection and quantification</article-title><source>Nucleic Acids Research</source><volume>38</volume><fpage>D792</fpage><lpage>D799</lpage><pub-id pub-id-type="doi">10.1093/nar/gkp1005</pub-id><pub-id pub-id-type="pmid">19906719</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stamatovic</surname><given-names>SM</given-names></name><name><surname>Keep</surname><given-names>RF</given-names></name><name><surname>Kunkel</surname><given-names>SL</given-names></name><name><surname>Andjelkovic</surname><given-names>AV</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Potential role of MCP-1 in endothelial cell tight junction “opening”: signaling via Rho and Rho kinase</article-title><source>Journal of Cell Science</source><volume>116</volume><fpage>4615</fpage><lpage>4628</lpage><pub-id pub-id-type="doi">10.1242/jcs.00755</pub-id><pub-id pub-id-type="pmid">14576355</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stinson</surname><given-names>WA</given-names></name><name><surname>Miner</surname><given-names>CA</given-names></name><name><surname>Zhao</surname><given-names>FR</given-names></name><name><surname>Lundgren</surname><given-names>AJ</given-names></name><name><surname>Poddar</surname><given-names>S</given-names></name><name><surname>Miner</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The IFN-γ receptor promotes immune dysregulation and disease in STING gain-of-function mice</article-title><source>JCI Insight</source><volume>7</volume><elocation-id>e155250</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.155250</pub-id><pub-id pub-id-type="pmid">36073546</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szego</surname><given-names>EM</given-names></name><name><surname>Malz</surname><given-names>L</given-names></name><name><surname>Bernhardt</surname><given-names>N</given-names></name><name><surname>Rösen-Wolff</surname><given-names>A</given-names></name><name><surname>Falkenburger</surname><given-names>BH</given-names></name><name><surname>Luksch</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Constitutively active STING causes neuroinflammation and degeneration of dopaminergic neurons in mice</article-title><source>eLife</source><volume>11</volume><elocation-id>e81943</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.81943</pub-id><pub-id pub-id-type="pmid">36314770</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>STING-associated vasculopathy with onset in infancy in three children with new clinical aspect and unsatisfactory therapeutic responses to tofacitinib</article-title><source>Journal of Clinical Immunology</source><volume>40</volume><fpage>114</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1007/s10875-019-00690-9</pub-id><pub-id pub-id-type="pmid">31705453</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wajant</surname><given-names>H</given-names></name><name><surname>Siegmund</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>TNFR1 and TNFR2 in the control of the life and death balance of macrophages</article-title><source>Frontiers in Cell and Developmental Biology</source><volume>7</volume><elocation-id>91</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2019.00091</pub-id><pub-id pub-id-type="pmid">31192209</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Warner</surname><given-names>JD</given-names></name><name><surname>Irizarry-Caro</surname><given-names>RA</given-names></name><name><surname>Bennion</surname><given-names>BG</given-names></name><name><surname>Ai</surname><given-names>TL</given-names></name><name><surname>Smith</surname><given-names>AM</given-names></name><name><surname>Miner</surname><given-names>CA</given-names></name><name><surname>Sakai</surname><given-names>T</given-names></name><name><surname>Gonugunta</surname><given-names>VK</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Platt</surname><given-names>DJ</given-names></name><name><surname>Yan</surname><given-names>N</given-names></name><name><surname>Miner</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>STING-associated vasculopathy develops independently of IRF3 in mice</article-title><source>The Journal of Experimental Medicine</source><volume>214</volume><fpage>3279</fpage><lpage>3292</lpage><pub-id pub-id-type="doi">10.1084/jem.20171351</pub-id><pub-id pub-id-type="pmid">28951494</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Welikovitch</surname><given-names>LA</given-names></name><name><surname>Do Carmo</surname><given-names>S</given-names></name><name><surname>Maglóczky</surname><given-names>Z</given-names></name><name><surname>Malcolm</surname><given-names>JC</given-names></name><name><surname>Lőke</surname><given-names>J</given-names></name><name><surname>Klein</surname><given-names>WL</given-names></name><name><surname>Freund</surname><given-names>T</given-names></name><name><surname>Cuello</surname><given-names>AC</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Early intraneuronal amyloid triggers neuron-derived inflammatory signaling in APP transgenic rats and human brain</article-title><source>PNAS</source><volume>117</volume><fpage>6844</fpage><lpage>6854</lpage><pub-id pub-id-type="doi">10.1073/pnas.1914593117</pub-id><pub-id pub-id-type="pmid">32144141</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Williams-Gray</surname><given-names>CH</given-names></name><name><surname>Wijeyekoon</surname><given-names>R</given-names></name><name><surname>Yarnall</surname><given-names>AJ</given-names></name><name><surname>Lawson</surname><given-names>RA</given-names></name><name><surname>Breen</surname><given-names>DP</given-names></name><name><surname>Evans</surname><given-names>JR</given-names></name><name><surname>Cummins</surname><given-names>GA</given-names></name><name><surname>Duncan</surname><given-names>GW</given-names></name><name><surname>Khoo</surname><given-names>TK</given-names></name><name><surname>Burn</surname><given-names>DJ</given-names></name><name><surname>Barker</surname><given-names>RA</given-names></name><collab>ICICLE-PD study group</collab></person-group><year iso-8601-date="2016">2016</year><article-title>Serum immune markers and disease progression in an incident Parkinson’s disease cohort (ICICLE-PD)</article-title><source>Movement Disorders</source><volume>31</volume><fpage>995</fpage><lpage>1003</lpage><pub-id pub-id-type="doi">10.1002/mds.26563</pub-id><pub-id pub-id-type="pmid">26999434</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wolf</surname><given-names>MJ</given-names></name><name><surname>Hoos</surname><given-names>A</given-names></name><name><surname>Bauer</surname><given-names>J</given-names></name><name><surname>Boettcher</surname><given-names>S</given-names></name><name><surname>Knust</surname><given-names>M</given-names></name><name><surname>Weber</surname><given-names>A</given-names></name><name><surname>Simonavicius</surname><given-names>N</given-names></name><name><surname>Schneider</surname><given-names>C</given-names></name><name><surname>Lang</surname><given-names>M</given-names></name><name><surname>Stürzl</surname><given-names>M</given-names></name><name><surname>Croner</surname><given-names>RS</given-names></name><name><surname>Konrad</surname><given-names>A</given-names></name><name><surname>Manz</surname><given-names>MG</given-names></name><name><surname>Moch</surname><given-names>H</given-names></name><name><surname>Aguzzi</surname><given-names>A</given-names></name><name><surname>van Loo</surname><given-names>G</given-names></name><name><surname>Pasparakis</surname><given-names>M</given-names></name><name><surname>Prinz</surname><given-names>M</given-names></name><name><surname>Borsig</surname><given-names>L</given-names></name><name><surname>Heikenwalder</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Endothelial CCR2 signaling induced by colon carcinoma cells enables extravasation via the JAK2-Stat5 and p38MAPK pathway</article-title><source>Cancer Cell</source><volume>22</volume><fpage>91</fpage><lpage>105</lpage><pub-id pub-id-type="doi">10.1016/j.ccr.2012.05.023</pub-id><pub-id pub-id-type="pmid">22789541</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>B</given-names></name><name><surname>Xu</surname><given-names>MM</given-names></name><name><surname>Fan</surname><given-names>C</given-names></name><name><surname>Feng</surname><given-names>CL</given-names></name><name><surname>Lu</surname><given-names>QK</given-names></name><name><surname>Lu</surname><given-names>HM</given-names></name><name><surname>Xiang</surname><given-names>CG</given-names></name><name><surname>Bai</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>HY</given-names></name><name><surname>Wu</surname><given-names>YW</given-names></name><name><surname>Tang</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>STING inhibitor ameliorates LPS-induced ALI by preventing vascular endothelial cells-mediated immune cells chemotaxis and adhesion</article-title><source>Acta Pharmacologica Sinica</source><volume>43</volume><fpage>2055</fpage><lpage>2066</lpage><pub-id pub-id-type="doi">10.1038/s41401-021-00813-2</pub-id><pub-id pub-id-type="pmid">34907359</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>M</given-names></name><name><surname>Qiqige</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Su</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>P</given-names></name><name><surname>Zhao</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Effects of tumor necrosis factor α (TNF-α) and interleukina 10 (IL-10) on intercellular cell adhesion molecule-1 (ICAM-1) and cluster of differentiation 31 (CD31) in human coronary artery endothelial cells</article-title><source>Medical Science Monitor</source><volume>24</volume><fpage>4433</fpage><lpage>4439</lpage><pub-id pub-id-type="doi">10.12659/MSM.906838</pub-id><pub-id pub-id-type="pmid">29949812</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>CA</given-names></name><name><surname>Huang</surname><given-names>YL</given-names></name><name><surname>Chiang</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Innate immune response analysis in COVID-19 and kawasaki disease reveals MIS-C predictors</article-title><source>Journal of the Formosan Medical Association = Taiwan Yi Zhi</source><volume>121</volume><fpage>623</fpage><lpage>632</lpage><pub-id pub-id-type="doi">10.1016/j.jfma.2021.06.009</pub-id><pub-id pub-id-type="pmid">34193364</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>G</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Feng</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Genomic-scale analysis of gene expression profiles in TNF-alpha treated human umbilical vein endothelial cells</article-title><source>Inflammation Research</source><volume>51</volume><fpage>332</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1007/pl00000312</pub-id><pub-id pub-id-type="pmid">12146724</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.101350.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Taniguchi</surname><given-names>Tadatsugu</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/057zh3y96</institution-id><institution>University of Tokyo</institution></institution-wrap><country>Japan</country></aff></contrib></contrib-group></front-stub><body><p>This study provides important insights into the pathogenesis of systemic autoinflammatory disease STING-associated vasculopathy with onset in infancy (SAVI). Specifically, the authors demonstrate the critical role of tumor necrosis factor (TNF) signaling in SAVI in mouse model. Overall, the data presented are convincing, supporting the author's conclusions.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.101350.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Taniguchi</surname><given-names>Tadatsugu</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/057zh3y96</institution-id><institution>University of Tokyo</institution></institution-wrap><country>Japan</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p>[Editors' note: this paper was reviewed by <ext-link ext-link-type="uri" xlink:href="https://www.reviewcommons.org/">Review Commons</ext-link>.]</p><p>Thank you for submitting your article &quot;Tissue inflammation induced by constitutively active STING is mediated by enhanced TNF signaling&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers at Review Commons, and the evaluation at <italic>eLife</italic> has been overseen by a Reviewing Editor and Tadatsugu Taniguchi as the Senior Editor.</p><p>Based on the previous reviews and the revisions, the manuscript has been improved but there are some remaining issues that need to be addressed, as outlined below:</p><p>We have read briefly the manuscript and accompanying comments, some of which are fair and some are not. We think this is a reasonable effort to understand the role of TNFRs in the pathogenesis of STING-associated vasculopathy. A significant amount of the disease observed is secondary to TNFRI activation and partially on TNFRII. Our greatest concern here relates to the use of Infliximab (an anti-human TNF antibody) rather than etanercept. There are studies which question the specificity of infliximab in the murine system (see for example, Anti‐inflammatory effects of infliximab in mice are independent of tumour necrosis factor α neutralization. Clin Exp Immunol. 2017 Feb; 187(2): 225-233. doi: 10.1111/cei.12872). Etanercept is known to bind to and inactivate both human and murine TNF. Although Infliximab has been used in the literature, its effects have been questioned over time and most recent studies preferentially use etanercept as a tool to block TNF-a in mice. The authors do present some results using etanercept (supplementary material). Unless the authors can show convincingly that murine TNF-a is being blocked in their system by Infliximab, this whole part of the study needs to be removed.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.101350.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Reviewer #1:</p><p>STING is a key signalling hub in the innate immune system, receiving multiple inputs from upstream activators (such as cGAS) and in turn triggering multiple downstream events (such as IFN induction, NF-κB signalling, autophagy, cell death). Mutations in the STING gene cause a rare inflammatory disease called SAVI. Using a previously established STING ki mouse that recapitulates some of the clinical observations in SAVI patients, this manuscript tests the hypothesis that TNF signalling drives pathology. Using anti-TNF antibody and TNF receptor knockout, the authors show that TNF indeed plays important roles in causing disease in this mouse model. For example, the loss of T cells and neurons is prevented when TNF signalling is blocked, and lung pathology is rescued in STING ki mice lacking TNF receptors. Overall, the manuscript is well written and laid out, and the experimental work is of a high technical standard.</p><p>Major comments</p><p>1. Most figures show pooled data from two independent experiments including a total of 5-8 mice. Given the variability in some of the readouts, this raises the question of whether there is sufficient statistical power to draw conclusions. For example, in Figure 2, the conclusion that &quot;Infliximab did not alter the expression of inflammatory mediators&quot; seems questionable given the results in Figure 2F and G. Did the authors perform a power calculation? What effect size can the authors detect given the variability and number of replicates? Similarly, in Figure 3, the authors conclude that &quot;Disruption of TNFR signaling did not significantly prevent T cell lymphopenia&quot;; however, with some more replicates, the data in Figure 3D would likely reach significance. Similar concerns apply to several panels in Figures 4 and 6 and to Figure S5M. Ideally, the authors should perform additional repeat experiments to increase the number of replicates. If that is not possible, power calculations need to be provided and conclusions should explicitly mention the minimum effect size that the author can detect given the small sample size (for example &quot;Infliximab did not alter the expression of inflammatory mediators more than x-fold&quot;).</p></disp-quote><p>We thank the reviewer for his/her time and for the constructive comments. Below please find our detailed responses to your points.</p><p>Thank you for this suggestion. However, it is not possible to repeat the treatment of mice with Infliximab for generation of more replicates. The blockade of TNF signalling by treatment with drugs did not cure the murine SAVI disease. According to animal welfare restrictions, we cannot perform additional treatment experiments with Infliximab or Etanercept.</p><p>We analysed the effect size d, f and power of all these presented results and collected them in table S4. Additional explanations about effect sizes were added in the corresponding text to Figures 2 and 3. The demonstrated results in Figure 4 and 6 already contain significant data. We did not include the calculation of effects sizes here. All effect size and power calculations are summarized in table S4.</p><disp-quote content-type="editor-comment"><p>2. The authors should not make unjustified overstatements. For example, STING KI; TNFR1/2 KO mice should not be referred to as a &quot;new mouse model&quot;. The manuscript simply tests the role of TNFR1/2 in the already published STING N153S model. In line 687, avoid using &quot;impressively&quot; and in line 734 avoid using &quot;massively&quot;.</p></disp-quote><p>Thank you for this suggestion. We changed this sentence into:…”these newly generated mouse lines of TNFR”…., see line 796. Additionally, in line 687 (actual line 705) we omitted “impressively” and in line 734 “massively produced” into “elevated” (actual line 752).</p><disp-quote content-type="editor-comment"><p>Minor comments</p><p>3. Line 767-769: The statement that spike activates cGAS is misleading, because this effect is an indirect consequence of cell-to-cell fusion (Liu et al. 2022).</p></disp-quote><p>Thank you for this suggestion. We changed this sentence into: Cell fusion caused by the SARS-CoV-2 spike protein is a potent… (actual line 785).</p><disp-quote content-type="editor-comment"><p>Reviewer #1 (Significance (Required)):</p><p>The main strengths of this study are (1) the use of complementary antibody-based and genetic methods to test the role of TNF signalling; (2) the use of multiple different readouts; and (3) the analysis of many different cell types / organ systems. The main weaknesses are (1) small sample sizes limiting statistical power (see above) and (2) the exclusive use of mouse models.</p><p>Overall, my opinion is that the advance is important, both fundamentally and clinically. Studies of this and the related V154M mouse model previously showed an important role of non-IFN pathways in driving disease. This study indicates that TNF signalling may cause pathology. This not only extends our understanding of STING's role in autoinflammation but also opens a direct therapeutic avenue using approved TNF targeting drugs.</p><p>This study will be primarily of interest to specialised audiences working on STING and SAVI, and secondarily to the wider innate immunity field.</p><p>This reviewer has expertise in the field of nucleic acid sensing, including cGAS-STING.</p></disp-quote><disp-quote content-type="editor-comment"><p>Reviewer #2:</p><p>In this paper, Luksch et al. (2024) examines the role of TNF signaling in STING-associated vasculopathy with onset in infancy (SAVI). By using pharmacological inhibition and genetic inactivation of TNF receptors in a murine SAVI model (STING ki), the research found that pharmacologically inhibiting TNF signaling improved T cell lymphopenia but had limited effects on lung disease. Genetic inactivation of TNFR signaling, particularly TNFR1, enhanced thymocyte survival and expanded the peripheral T cell pool, reducing inflammation and neurodegeneration. The development and progression of severe lung disease in STING ki mice are also reliant on TNFR1 signaling, while TNFR2 deletion did not alleviate lung inflammation. The authors also explored the severe inflammatory lung disease manifestation, showing that primary lung endothelial cells in STING ki mice allowed more neutrophil attachment compared to those in STING WT mice, indicating chronic STING activity in endothelial cells disrupts the endothelial barrier and promotes severe lung disease. The study highlights TNFR signaling as crucial in SAVI and COVID-19 progression and suggests blocking TNFR1 signaling as a potential therapeutic approach for both diseases.</p><p>Major comments:</p><p>The paper establishes a strong connection between TNFR1 depletion and the reduction of SAVI disease severity in lung and neuroinflammation, suggesting TNFR1 blockade as a viable therapeutic strategy for SAVI. To strengthen the arguments and improve the therapeutic potential, the authors should address the following major comments:</p><p>1. The authors conclude that TNFR1 signaling drives murine SAVI disease, as evidenced by the reduced severity of lung disease in TNFR1 -/- mice. While the genetic model is convincing, the discrepancy between pharmacological inhibition and genetic models needs clarification. Before attributing the pharmacological failure to late administration, have the authors considered that Infliximab might not sufficiently deplete TNF to achieve therapeutic benefits? In figure 2H, serum TNF levels were not significantly altered in STING ki mice treated with Infliximab. Have the authors considered using other TNF inhibitors or alternative methods to measure TNF depletion efficacy in STING ki murine models, such as qPCR, flow cytometry, or immunohistochemistry in lymph nodes or lung tissues?</p></disp-quote><p>We thank the reviewer for his/her time and for the constructive comments. Below please find our detailed responses to your points.</p><p>Thank you for this suggestion. In a preliminary experiment, we already treated STING WT and STING ki mice with Etanercept which is not included in the paper. 3-week-old mice were treated with subcutaneously injection of 25 mg/kg Etanercept or saline, twice per week, for 7 weeks. After treatment, all mice were euthanized and single cell suspensions of blood and spleen were used for flow cytometry analysis. Lung tissue was harvested for histological analysis. Quantification of gene expression was performed by snap frozen lung and kidney tissue and quantification of secreted proteins was analysed by snap frozen serum.</p><p>The transcription of ISGs and proinflammatory mediators in lung tissue was not significantly improved by the Etanercept treatment of mice, see <xref ref-type="fig" rid="sa2fig1">Author response image 1A</xref> – D. Interestingly, the amount of secreted CXCL9 in the serum was reduced in Etanercept treated mice compared to vehicle treated mice (E). We concluded that our treatment strategy had no impact in the manifestation and progression of murine SAVI disease, in highly inflamed tissues / organs. However, we found a reduction (partially significant) of proinflammatory mediator transcriptions in the kidney of Etanercept treated mice compared to vehicle control mice. Murine SAVI disease is a systemic autoinflammatory disease without histological alteration in kidney tissue of 10 weeks old mice. Remarkably, transcription of ISGs and proinflammatory mediators is highly upregulated in SAVI mice. Treatment with Etanercept improved this aberrant gene expression in murine SAVI influenced tissue / organ (<xref ref-type="fig" rid="sa2fig1">Author response image 1I</xref> – K). These results encouraged us to perform the treatment with infliximab because we expected a more pronounced effect since infliximab can bind the monomeric and trimeric form while etanercept can only bind to the active trimeric from of TNF.</p><fig id="sa2fig1" position="float"><label>Author response image 1.</label><caption><title>Etanercept treatment of STING WT (in black) and STING ki (in red) mice.</title><p>(<bold>A</bold>) Relative expression level of Cxcl10, (<bold>B</bold>) Mx1, (<bold>C</bold>) Tnf and (<bold>D</bold>) Il1b in lung tissue of Etanercept or saline treated STING WT and STING ki mice. (<bold>E</bold>) Quantification of CXCL9, (<bold>F</bold>) CXCL10, (<bold>G</bold>) IL-6 and (<bold>H</bold>) TNF in serum samples from STING WT and STING ki mice after treatment. (<bold>I</bold>) Relative expression level of Cxcl10, (<bold>J</bold>) Mx1, (<bold>K</bold>) Tnf and (<bold>L</bold>) Il1b in kidney tissue of treated mice.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-101350-sa2-fig1-v2.tif"/></fig><disp-quote content-type="editor-comment"><p>2. The TNF pathway exhibits redundancy, as multiple signaling molecules or pathways can compensate for the loss of TNF function to maintain cellular processes and immune responses. The authors showed that thymocytes of STING ki mice lacking TNFR1/2 expressed significantly lower levels of IFN-related genes (Cxcl10, Sting1), and mice lacking TNFR1 and TNFR1/2 expressed reduced levels of NF-κB-related genes. Does this imply that IFN and NF-κB pathways are downstream of TNF signaling driving SAVI progression? It would be valuable to hear the authors' comments or postulations on the potential mechanisms of TNF driving SAVI progression in the discussion, and the methods to dissect the mechanisms further using genetic or pharmacological methods.</p></disp-quote><p>Thank you for this suggestion. STING is a key player in various proinflammatory mechanism and is directly involved in IFN and NF-κB signalling. We assume that these signalling pathways are adaptable to various proinflammatory situations. Knock out of TNFR1 and TNFR1/2 results in a strong inhibition of all inflammatory reactions in the whole organisms. We think, it is not possible to conclude mechanisms of murine SAVI manifestation and progression from the results of these mouse lines only. These observations provide new hypothesis, but cannot completely explain the mechanism.</p><disp-quote content-type="editor-comment"><p>3. The authors mentioned that the pharmacological inhibition of TNF by Infliximab is ineffective due to late administration compared to the onset of SAVI. How would this affect the therapeutic treatment of TNF if the treatment is going to be later than the disease onset? Can the authors elaborate on the potential ways to circumvent the timing of treatment? Would TNFR1 antagonists experience the same issue? To understand disease progression and optimal targeting times, the creation of an inducible TNFR1/2 -/- mouse model could be beneficial. This is optional, but the authors are encouraged to comment on improving TNFR1/2 -/- mouse SAVI models to further study the therapeutic potential of TNF signaling blockage in treating SAVI.</p></disp-quote><p>We agree with the suggestion. In the next project, we want to generate STING ki mice with inducible knock out.</p><disp-quote content-type="editor-comment"><p>Minor comments:</p><p>4. The authors separate STING WT and STING ki into different graphs, which can sometimes make it hard to compare STING WT and STING ki baseline levels. It would be beneficial to merge the two genotypes into single graphs for easier comparison.</p></disp-quote><p>Thank you for this suggestion. In the first version of this manuscript, we collected results from STING WT and STING ki mice in one graph with 8 bars in different colours and textures in the case of TNFR knock out lines. These graphs were overloaded and very confusing. It is was not possible to mark statistical calculations inside these graphs without losing the focus. Hence, we created the demonstrated design of graphs. We think this is the most convincing version.</p><disp-quote content-type="editor-comment"><p>5. Figure S5 lacks statistical annotations, although the legends mention them. Are the statistics usually shown when a comparison is mentioned in the text, or are they only displayed when the differences are significant? It would be helpful if the authors could clarify this and ensure that all relevant statistical comparisons are clearly reflected in the graphs, regardless of the significance level. This consistency would improve the clarity and interpretation of the data presented.</p></disp-quote><p>Thank you for this suggestion. We removed the significance level from the legend of Figure S5 (actually line 1199).</p><disp-quote content-type="editor-comment"><p>6. The authors did an excellent job discussing the study's implications, but some of this content could be moved to the introduction. The hypothesis that &quot;tumor necrosis factor (TNF) signaling is involved in the manifestation and progression of murine SAVI disease&quot; can be introduced more naturally once the authors present previous findings on TNF's association with various autoimmune disorders. This would set a clear context for the study's objectives and rationale.</p></disp-quote><p>We agree with this suggestion and inserted the sentence: “In our previous investigations, we observed an elevated transcription of <italic>Tnf</italic> in spleen and thymus of STING ki mice (Siedel et al., 2020).” (actual line 89/90).</p><disp-quote content-type="editor-comment"><p>General Assessment: The study identifies enhanced TNF signaling as a driver of SAVI and specifies TNFR1 blockage as a promising treatment to reduce disease severity. It thoroughly characterizes pharmacological inhibition and genetic perturbations of TNF signaling in murine SAVI models and creates a novel mouse model for studying TNF-targeted therapies in SAVI treatment.</p><p>However, the study is limited in characterizing the discrepancy between pharmacological inhibition and genetic depletion of TNF and understanding the underlying mechanisms of TNF driving chronic STING activation and tissue inflammation.</p><p>Advances: The study extends knowledge in the field by demonstrating that enhanced TNF signaling drives SAVI, establishing causation rather than mere correlation. The authors provide strong rationale for treating SAVI with TNF inhibitors/blockage, previously used in other autoimmune disorders like IBD or Crohn's disease, but not in SAVI. They also present a valuable genetic model for studying TNFR signaling blockage in SAVI progression, which is important for both the field of SAVI and future therapy development.</p><p>Audience: The research provides translational and clinical insights by suggesting that targeting TNFR1 signaling could inspire novel treatments for SAVI. The study also advances basic research on SAVI disease progression. Immunologists and clinicians studying and treating autoimmune disorders are the intended audience, but the findings have broader implications. The study highlights the potential role of TNF signaling in COVID-19 disease progression and treatment, thus attracting interest beyond the field of autoimmune disorders.</p><p>Field of expertise:</p><p>cGAS-STING regulation in chromosomally unstable cancers, genomic instability, nuclear envelope rupture and repair</p><p>Do not have sufficient expertise in:</p><p>Immunological underpinning of autoimmune disorders, clinical models or manifestations of SAVI</p></disp-quote><disp-quote content-type="editor-comment"><p>Reviewer #3:</p><p>Uncontrolled activation of STING is linked to autoinflammatory disease &quot;STING-associated vasculopathy with onset in infancy (SAVI)&quot;. The authors had previously published a mouse model of SAVI, which was generated by knocking in the disease causing variant N153S into the endogenous murine Sting1 gene (STING ki) (Luksch et.al., 2019). In the current study, the author further investigated the role of tumor necrosis factor (TNF) signaling in manifestation and progression of murine SAVI disease by using the approach of pharmacologic and genetic inhibition of TNF receptors TNFR1 and TNFR2. Overall, the authors were able to demonstrate the following novel findings:</p><p>1) Infliximab treatment of STING ki mice significantly increased the number of blood CD8<sup>+</sup> T cells and thymic cells count. The authors claimed that the pharmacological inhibition of TNF signalling has a partial rescue effect of T cell lymphopenia. However, pharmacologic inhibition of TNF signalling however has no effect on lung disease.</p><p>2) On the other hand, STING ki;Tnfr1-/- (lacking TNFR1) showed the similar modest rescue of the CD8<sup>+</sup> T and CD4<sup>+</sup> T cells in blood compared to the WT C57BL/6 (BL6) but not with STING ki;Tnfr2-/- (lacking TNFR2). STING ki;Tnfr1-/-, STING ki;Tnfr2-/- and STING ki;Tnfr1/2-/- had modest rescue of thymic cell count and reduced spleen cell count (reduced splenomegaly). Along with the rescued thymic content and reduced splenomegaly, genetic ablation of TNF signalling (STING ki;Tnfr1-/-) also prevented manifestation of severe inflammatory lung disease.</p><p>3) To investigate the role of lung endothelial cells in the development of interstitial lung disease, primary murine lung endothelial cells from STING WT, STING ki and STING WT;Tnfr1/2-/- and STING ki;Tnfr1/2-/- mice were isolated and bulk RNAseq was performed. This showed decreased level of several proinflammatory cytokines (e.g. Tnf, Il1b) and chemokines (e.g. Cxcl1, Cxcl2, Cxcl9, Cxcl10, Ccl2, Ccl3 and Ccl4) in STING ki mice lacking TNFR1/2 compared to STING ki mice.</p><p>4) Neutrophils were isolated from bone marrow and were added to cultured primary lung endothelial cell monolayers. The experiments demonstrated that the attachment and transmigration of neutrophil cells were dependent on expression of STING gain-of-function mutation in endothelial cells.</p><p>A few points require clarification before publication of this study.</p><p>1. Tnfr1-/-, Tnfr2-/- and Tnfr1/2-/- did not show any statistical significant improvement of thymic cell count in STING ki mice. As such, the statement in the conclusion/summary section of discussion regarding Tnfr1 can restore thymocyte numbers should be toned-down.</p></disp-quote><p>We thank the reviewer for his/her time and for the constructive comments. Below please find our detailed responses to your points.</p><p>Thank you for this suggestion. In Figure 4 E, we demonstrated that knock out of TNFR1 leads to increasing of SP CD8 thymocyte count and partially of SP CD4 thymocyte count (Figure 4 D). In agreement with this suggestion, we marked this subpopulation of thymocytes in the discussion and summary section, see actual line 684 and see actual line 794.</p><disp-quote content-type="editor-comment"><p>2. The section on Neuroinflammation and neurodegeneration and dependency of TNFR1/2 signaling is very currently difficult to follow (based on how the data are presented in figures and text). This section requires to be re-written for clarity.</p></disp-quote><p>Thank you for this suggestion. We re-wrote this section, see line 472 – 499.</p><p>“Neuroinflammation and neurodegeneration in dependency of TNFR1/2 signaling</p><p>The extent of inflammation in mouse brain resulting from constitutive activation of STING N153S was reported by quantifying the density of Iba1-positive microglia (Figure 5 A). Consistent with our previous findings (Szego et al., 2022), the density of Iba1-positive microglia in the <italic>substantia nigra</italic> was higher in STING ki;BL6 mice than in STING WT mice (Figure 5 B). TNFR deficiency did not affect neuroinflammation because there was no significant difference between the density of Iba1-positive microglia between STING ki;BL6 mice and STING ki;<italic>Tnfr1/2<sup>-/-</sup></italic> mice (Figure 5 B). This suggests that the TNF pathway is not required for STING-induced microglia activation in the <italic>substantia nigra</italic>.</p><p>In addition, we measured the extent of STING-induced astrogliosis by quantifying the density of GFAP-positive cells (Figure 5 A). Consistent with our previous findings, the density of GFAP-positive astroglia was higher in STING ki than in STING WT mice (Figure 5C). Yet, as for microglia, there was no significant difference between the density of GFAP-positive astroglia between STING ki;BL6 mice and STING ki;<italic>Tnfr1/2<sup>-/-</sup></italic> mice (Figure 5 C), suggesting that the TNF pathway is not required for STING-induced astrogliosis in the <italic>substantia nigra</italic>.</p><p>Finally, we measured the extent of STING-induced neurodegeneration by quantifying the density of TH-positive dopaminergic neurons in the <italic>substantia nigra</italic> (Figure 5A)<italic>.</italic> As in our previous findings, the density of TH-positive neurons was lower in STING ki;BL6 mice than in STING WT mice (Figure 5 D). The density of TH-positive neurons in the <italic>substantia nigra</italic> of STING ki;<italic>Tnfr1/2<sup>-/-</sup></italic> mice was higher than the density of TH-positive neurons in the <italic>substantia nigra</italic> of STING ki;BL6 mice (Figure 5 D), suggesting that the STING-induced degeneration of TH-positive neurons was blunted in <italic>Tnfr1/2<sup>-/-</sup></italic> mice and that TNFR1/2 are involved in the STING-induced degeneration of dopaminergic neurons.</p><p>Hence, there is a discrepancy between STING-induced effects on glial cells as opposed to STING-induced effects on neurons. The dependence of STING-induced neurodegeneration but not glial response on TNFR1/2 suggests that the STING-induced degeneration of dopaminergic neurons is not a direct consequence of microglia or astroglia activation. This is consistent with the emerging concept of a neuron-specific inflammatory response (Welikovitch et al., 2020).”</p><disp-quote content-type="editor-comment"><p>The powerful use of in vivo genetic KO models and TNF inhibitor makes this study a valuable contribution to the field – helping further decipher the importance of the NF-ΚB/TNF branch of STING in SAVI (knowledge gap). The audience for this work would be specialised to STING biology and potential clinical treatments of SAVI.</p><p>Our expertise is in nucleic acids sensing (such as STING) and auto-immunity.</p></disp-quote><p>[Editors’ note: what follows is the authors’ response to the second round of review.]</p><disp-quote content-type="editor-comment"><p>Based on the previous reviews and the revisions, the manuscript has been improved but there are some remaining issues that need to be addressed, as outlined below:</p><p>We have read briefly the manuscript and accompanying comments, some of which are fair and some are not. We think this is a reasonable effort to understand the role of TNFRs in the pathogenesis of STING-associated vasculopathy. A significant amount of the disease observed is secondary to TNFRI activation and partially on TNFRII. Our greatest concern here relates to the use of Infliximab (an anti-human TNF antibody) rather than etanercept. There are studies which question the specificity of infliximab in the murine system (see for example, Anti‐inflammatory effects of infliximab in mice are independent of tumour necrosis factor α neutralization. Clin Exp Immunol. 2017 Feb; 187(2): 225-233. doi: 10.1111/cei.12872). Etanercept is known to bind to and inactivate both human and murine TNF. Although Infliximab has been used in the literature, its effects have been questioned over time and most recent studies preferentially use etanercept as a tool to block TNF-a in mice. The authors do present some results using etanercept (supplementary material). Unless the authors can show convincingly that murine TNF-a is being blocked in their system by Infliximab, this whole part of the study needs to be removed.</p></disp-quote><p>We thank you and the reviewers for your time and for the constructive comments which have helped us to substantially improve the manuscript. We have extensively revised the manuscript and omitted experimental data.</p></body></sub-article></article>